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CHAPTER 1. Strategies to obtain target-specific metal complexes as imaging agents
Portions of this chapter are reprinted or adapted with permission from Vithanarachchi, S. M.;
Allen, M. J. Current Molecular Imaging 2012, 1, 12–25. Copyright Bentham Science Publishers.
Introduction
Imaging techniques play a vital role in diagnostic medicine and medical research by
aiding with the detection of diseases as well as the monitoring of disease progression and
treatment. These imaging modalities include single photon emission computed tomography,
positron emission tomography, ultrasound, magnetic resonance imaging (MRI), photoacoustic
tomography, and fluorescence imaging, and reviews describing the advantages and limitations of
each modality have been published elsewhere.1–6 This thesis focuses on MRI because my
research explored the utility of GdIII-containing complexes to achieve targeted imaging with
MRI. MRI is a powerful, non-invasive imaging technique that does not use ionizing radiation
and has the capability to generate three-dimensional images of deep tissue with good spatial
resolution (25–100 µm).6
Conventional MRI images are produced by mapping either the relaxation rates or
densities of the nuclear spins of water protons in a magnetic field. Differences in relaxation rates
are due in part to the chemical composition of the surrounding environment; however, the
inherent levels of signal intensity that result from the differences in relaxation rates of water
protons are often not sufficient to produce satisfactory contrast. Therefore, chemicals known as
contrast agents are used in MRI to catalytically accelerate the relaxation rate of water protons to
obtain contrast-enhanced images. Paramagnets including GdIII, MnII, and MnIII are referred to as
“T1-shortening agents” because of their influence on longitudinal (T1) relaxation rates, and
superparamagnetic iron oxide (SPIO) particles are referred to as “T2-shortening agents” because
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of their influence on transverse (T2) relaxation rates.7 The ability of a contrast agent to influence
contrast is measured in terms of relaxivity, and relaxivity changes in response to changes in
physical parameters including magnetic field strength, temperature, and solvent composition.
This dependence of relaxivity on measurement conditions often prevents a meaningful direct
comparison of agents in different studies. Hence, in this chapter, physical parameters are
reported for each example to avoid misinterpretation that could arise due to direct comparison of
agents measured under different conditions (Table 1.1).
In current clinical MRI (1.5–3 T), GdIII-based complexes are the most commonly used
contrast agents, and these agents are non-specific; they do not accumulate in particular tissues or
organs of interest. Non-specific contrast agents are useful in the imaging of pathologies like
tumors, lesions, and inflammation because these agents aid in the differentiation of healthy and
diseased tissues based on vascular volume, vascular perfusion, and vascular permeability.8 While
these non-specific contrast agents are used in ~35% of clinical scans,9 their utility in the early
detection of disease and imaging of specific biological regions is limited. This limitation arises
because diseases often do not display changes in vasculature, and if observable changes in
vasculature occur, they are likely to occur in later stages of diseases. One method to address the
limitation of non-specificity is the use of targeted contrast agents. Since the first descriptions of
targeted contrast agents,10,11 this topic has become a focus in the field of MRI and contrast agent
research because of the potential to enable molecular imaging in addition to anatomical imaging.
The importance of targeted contrast agents has been described in several recent reviews.8,3,12–18
These reviews discuss the development and properties of T1- and T2-shortening agents and the
use of different biomarkers as targets. In this chapter, targeted contrast agents are described for
proton MRI that were developed during the last ten years using two different synthetic strategies
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with a focus on agents that have been tested both in vitro and in vivo to emphasize limitations
that must be overcome to enable the clinical use of targeted contrast agents.
The design of target-specific contrast agents involves two types of strategies: the most
common strategy is to conjugate a contrast agent with an antibody, peptide, or a small organic
molecule that enables interactions with a target. A second strategy is to transform a contrast
agent directly into the targeting moiety by mimicking the structure of a molecule that naturally
interacts with a desired target. The development of targeted contrast agents with these two
strategies has led to successful targeting in vitro, and some agents have been successfully
translated to enable in vivo visualization of targets. The remainder of this chapter is organized
into these two strategies: conjugation and mimicking.
The conjugation strategy
Direct conjugation of derivatives of clinically approved contrast agents to peptides,
antibodies, or small organic molecules is a popular and relatively simple method of achieving
target specificity. All directly conjugated contrast agents contain three parts: a targeting moiety,
a contrast-enhancing unit, and a linker that connects the other two parts (Figure 1.1). When
linking the contrast-enhancing unit and targeting moiety, either metalate-then-conjugate or
conjugate-then-metalate methods can be used,19 and conjugation generally results in the
formation of biologically stable amides, ethers, thioesters, or triazoles. Low molecular weight
(≤30 kDa) targeted contrast agents are desirable because their small size enables diffusion to
small areas and facile clearance, but this type of targeted contrast agent faces the challenge of
low sensitivity: with small GdIII-based contrast agents, micromolar or greater concentrations are
needed to achieve satisfactory contrast in vivo.20, 21 Therefore, contrast agents that possess both
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high relaxivity and long circulation times are desirable to lower the dose of contrast agent. To
increase sensitivity, targeting moieties and GdIII-containing complexes are conjugated to
macromolecules including dendrimers, polymers, proteins, liposomes, and nanoparticles. These
agents obtain high relaxivity by slowing the molecular tumbling rate, by combining several
contrast-enhancing units per targeting moiety, or both. In the following section, the use of the
conjugation strategy is described in the synthesis of targeted imaging agents using both a single
contrast-enhancing unit (monomeric) and multiple contrast-enhancing units (multimeric), and the
selectivity and sensitivity of the resulting agents is described for in vitro and in vivo experiments.

Figure 1.1. Schematic representation of the basic units of targeted
contrast agents synthesized using the conjugation strategy.
Monomeric target-specific contrast agents
Monomeric targeted contrast agents contain one contrast-enhancing unit per targeting
moiety; therefore, to achieve satisfactory contrast enhancement with these agents, targets with
high expression levels need to be selected. Examples of such highly expressed targets include
biomarkers associated with tumors; consequently, many monomeric tumor-targeted contrast
agents are reported. Conjugation of steroids with contrast agents enables targeting of receptors
on tumor cells because hormone receptors are over-expressed by various tumors. 21Hydroxyprogesterone and 17β-estradiol are steroids that interact with progesterone receptors and
estrogen receptors that are over-expressed by uterine, breast, ovarian, and prostate carcinomas.
These two steroids were conjugated with GdIII-containing complexes to produce monomeric
contrast agents 1.2a and 1.2b, respectively (Figure 1.2).22,23 The relaxivity of 1.2a is 5.35 mM–
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s (1.41 T, 37 °C, and 1% dimethylsulfoxide in water), and the relaxivity of 1.2b is 6.8 mM–1s–1

(9.4 T and phosphate buffered saline (PBS)). Because these relaxivity values are similar to those
of clinically used non-specific agents,20,24 doses similar to those used for non-specific agents are
needed to enable good contrast (0.15 mmol/kg for 1.2a and 0.075 mmol/kg for 1.2b). In vivo
imaging of xenograft mice using intraperitoneal or subcutaneous injections of 1.2a at 7.05 T
resulted in contrast enhancement of progesterone-receptor-positive tumors with respect to
progesterone-receptor-negative tumors (Figure 1.3). Furthermore, agent 1.2a labels tissues that
express progesterone receptors including the uterus and ovaries.22 Imaging of xenograft mice
using 1.2b (tail-vein injection at 9.4 T) demonstrated the targeting efficiency of this agent toward
estrogen-receptor-positive tumors by enhancing contrast relative to estrogen-receptor-negative
tumors.23 The success of these two agents in enhancing contrast in tumors relies on the over
expression of receptors in tumors relative to normal tissues.
Integrins are other receptors targeted for imaging. Integrin-targeted contrast agents have
the potential to enable the detection of angiogenesis and thrombosis. The cyclic peptide cRGD is
a widely used targeting moiety for integrins.25−27 An αIIbβ3 integrin-receptor-targeted agent
reported by Fayad and co-workers to detect thrombosis demonstrates the importance of high
receptor concentration to obtain good contrast enhancement with monomeric agents.25 Their
contrast agent, 1.2c, consists of cRGD conjugated to Gd III 1,4,7,10-tetraazacyclododecaneN,N´,N´´,N´´´-tetraacetic acid (DOTA). This agent has a relaxivity of 9 mM–1s–1 (1.41 T and 40
°C) and binds with the αIIbβ3 receptor as well as the αVβ3 receptor. In vivo studies with mouse
models of thrombosis demonstrated the ability of 1.2c to increase contrast of activated platelets
with a 0.1 mmol/kg dose injected in the tail-vein. The reason for the success of 1.2c as a
thrombosis-targeted contrast agent is the high expression of the αIIbβ3 receptor (40,000 per
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platelet) in platelets relative to αVβ3 (~1,500 per platelet).28 When the expression level of a target
is low, larger amounts of monomeric agents are needed to achieve contrast enhancement. For
example, cRGD-conjugated contrast agent 1.2d (Figure 1.2) was studied as a means to
selectively image the αVβ3 integrin receptor that is over-expressed in hepatocelluler carcinomas.27
The relaxivity of contrast agent 1.2d is 7.4 mM–1s–1 (1.5 T and 25 °C), and in vivo imaging of Hras12V transgenic mice bearing hepatocellular carcinomas at 1.5 T (tail-vein injection of 1.43
mmol/kg of 1.2d) enhanced contrast of the tumor region. Tumor cells used in this study have a
low concentration of αVβ3 receptors, and the contrast agent has a moderate specificity for these
receptors; thus, the high dose used in this study was needed to saturate the receptors.
Table 1.1. Conditions used for relaxivity measurements and MR imaging
contr
ast
agent

field strength (T)
relaxivity
measurem
ents

tempera
ture for
relaxivit
y (°C)

medium for
relaxivity
measurements

relaxivity
(T1) (mM–
1 –1 a
s )

relaxivity
(T2) (mM–
1 –1 a
s )

in vivo
imaging dose

in vitro
imaging
concentrat
ions

refere
nce

21

NR

4.73

NR

0.15 mmol/kg

NR

22

5.35

6.14

0.15 mmol/kg

NR

22

6.8

NR

NR

23

NR

0.075
mmol/kg
0.1 mmol/kg

NR

25

1.2a

4.7

in
vivo/
in
vitro
studi
es
7.05

1.2a

1.41

7.05

37

1.2b

9.4

9.4

NR

1% DMSO in
water
PBS

1.2c

1.41

9.4

40

NR

9

1.2d

1.5

1.5

25

NR

7.4

4

1.43 mmol/kg

NR

27

1.2e

9.4

9.4

NR

PBS

4.7

NR

NR

23

1.2f

4.7

4.7

NR

aqueous

1.28

NR

0.5 mM

29

1.2g

1.41

2

37

water

21

30

0.075
mmol/kg
0.2
µmol/mouse
0.03 mmol/kg

NR

30

1.2h

1.41

4.7

37

21

30

31

0.47

NR

25

7.7

NR

0.24
µmol/mouse
NR

NR

1.2i

Tris buffer,
pH 7
pH 7.4

NR

33

1.2j

4.7

NR

37

water

5.5

6.9

NR

NR

24

1.2j

3

NR

37

water

5.3

6.1

NR

NR

24

1.2j

1.5

NR

37

water

5.2

5.9

NR

NR

24

1.2k

0.47

NR

37

water

5.6

NR

NR

NR

26

1.2l

3

3

RT

NR

4.22

4.45

0.1 mmol/kg

NR

34

7
NR

7

NR

NR

NR

NR

1.2n

9.4

9.4

21

water

5.2

1.2n

1.41

9.4

40

water

5.1

1.2n

0.47

9.4

40

water

5.8

1.2m

NR

35

NR

0.4–2
mg/mouseb
1.14 µmol/kg

0.1 mM

38, 39

NR

1.14 µmol/kg

0.1 mM

38, 39

1.14 µmol/kg
4 µmol/kg

0.1 mM

38, 39

NR

40, 41

NR

4 µmol/kg

NR

40, 41

NR

0.025
mmol/kg
0.025
mmol/kg
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Figure 1.2. Monomeric targeted contrast agents synthesized using the conjugation strategy.
Contrast agent 1.2h is adapted with permission from reference 31. Copyright 2011 Qiao et al.

Figure 1.3. Representative in vivo images of targeted contrast agents: contrast enhancement of
progesterone-receptor (PR)-positive and PR-negative tumors using monomeric conjugated
contrast agent 1.2a. Scale bars represent 5 mm, and arrows point to tumors. Adapted with
permission from reference 22. Copyright 2011 American Chemical Society.
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The integrin-receptor-targeted examples 1.2c and 1.2d demonstrate the importance of
biomarker expression level for targeted imaging. However, in vitro success is often difficult to
translate in vivo even with biomarkers expressed at high levels and high-affinity targeting
moieties. For example, the estrogen-receptor-targeted contrast agent 1.2e (Figure 1.2) reported
by Degani and co-workers has a relaxivity of 4.7 mM–1s–1 (9.4 T and PBS). However, agent 1.2e
(using same dose as 1.2b) was not able to produce significant enhancement in vivo despite a
higher in vitro binding affinity with a binding inhibition constant, Ki, of 0.13 µmol/L for estrogen
receptors than 1.2b (Ki = 0.97 µmol/L).23 This discrepancy likely was due to the accumulation of
1.2e in muscle tissues causing a reduction in the effective dose for estrogen-receptor-positive
tumors.
Further highlights of the inconsistencies that are often observed between in vitro and in
vivo systems are exemplified by two studies that target the folate receptor, which is found in high
concentrations in tumors. Folate-conjugated monomeric contrast agent 1.2f (Figure 1.2) has a
low relaxivity of 1.28 mM–1s–1 (4.7 T and aqueous solution).29 In vitro studies of 1.2f with
human folate-receptor-positive ovarian carcinoma (IGROV-1) cell lines did not produce signal
enhancement; however, inductively coupled plasma-mass spectrometry results with competitive
binding experiments confirmed the uptake of 1.2f by the cells. Despite the negative imaging
results of the in vitro studies, in vivo studies at the same field strength demonstrated increased
contrast of tumors in xenograft mouse models using a micromolar dose of 1.2f delivered
intravenously. Conversely, the folate-related agent 1.2g reported by Wang and co-workers
containing a dimeric GdIII chelate conjugated to folate has a high relaxivity of 21 mM –1s–1 per
GdIII ion (1.41 T, 37 °C, and water).30 In vitro studies with IGROV-1 cells confirmed the uptake
of 1.2g through folate receptors. While contrast agent 1.2g was unable to enhance contrast in
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tumors implanted in rat models in vivo at 2 T (0.03 mmol/kg dose), the relaxation rate in the
tumor increased and ∆R1 (the difference between the T1 relaxation rates before and 1 h after
contrast enhancement) was 0.214 s–1 for 1.2g relative to non-targeted agents (0.112 s–1),
suggesting that the agent was retained in the tumor. Hence, the poor enhancement obtained in
this study likely is not related to the selectivity of the contrast agent.
Conjugating a high relaxivity agent to a targeting moiety often is advantageous because it
leads to an increase in contrast with lower doses of agent. Recently, Yang and co-workers
reported contrast agent 1.2h targeted to human epidermal growth factor receptor type 2 (HER2)
(Figure 1.2) using a designed protein chelator for GdIII, and agent 1.2h has a high relaxivity (21
mM–1s–1, 1.41 T, 37 °C, and tris(hydroxymethyl)aminomethane (Tris) buffer at pH 7).31 The
contrast agent is conjugated to a HER2 affibody as the targeting moiety, a fluorescent dye to
enable tracking by fluorescence microscopy, and polyethylene glycol moieties to achieve
biocompatibility. Agent 1.2h demonstrated increased in vivo enhancement of tumors in xenograft
mice using a tail vein injection of 100 fold lower dose (0.24 µmol per mouse) than is used
commonly with clinical contrast agents for routine MR imaging experiments.
Although, a protein was used as the chelating moiety in the previous example, more often
proteins are used as targets. There are several contrast agents that label human serum albumin,
including GdIII 3,6,10,16-tetraazabicyclo[10.3.1]hexadecane-3,6,10-tris(methanephosphonates)
1.2i, MS-325 1.2j, and GdIIIDOTA-deoxycholic acid 1.2k (Figure 1.2).26,32,33 These agents bind
to albumin leading to increased circulation times; consequently, they are used as blood pool
imaging agents. Fibrin and collagen are other well explored proteins for targeted imaging
because they are found in high concentrations in angiogenesis, thrombosis, atherosclerosis, and
other wound-healing processes. The cyclic decapeptide cCGLIIQKNEC (CLT1) conjugated to
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GdIII diethylenetriaminepentaacetic acid (DTPA), 1.2l, (Figure 1.2) is a fibrin–fibronectinlabeling agent with a relaxivity of 4.22 mM–1s–1 (3 T and room temperature).34 In vivo tumor
imaging of human colon cancer xenografts in mice showed enhancement of tumors using a 0.1
mmol/kg dose because of the high concentration of fibrin–fibronectin associated with the
neovascularization of tumors.
Imaging diseases in the brain is more challenging than in other parts of the body because
of the tight regulation in transportation of compounds across the bloodbrain barrier (BBB).
Some diseases like brain tumors disrupt the BBB allowing contrast agents to accumulate in the
interstitial spaces that outline the tumor region. However, many other abundant neuropathologies
including Alzheimer’s disease and multiple sclerosis do not disrupt the BBB during early stages
of the diseases. Hence, the synthesis of targeting biomarkers to image neuropathology with MRI
is an active area of research because of the current lack of in vivo detection methods. β-Amyloid
peptides and myelin are two components that have been investigated as targets.35–39
β-Amyloid plaques are potential biomarkers for imaging Alzheimer’s disease.35–37 A
derivative of amyloid peptide conjugated with GdIII-containing complexes, 1.2m, was found to
label amyloid plaques in vivo.35 MRI imaging at 7 T of brains removed from transgenic mice
(APP-PS1) that were injected intravenously with 1.2m demonstrated contrast enhancement of
plaques. This result implies that 1.2m has the ability to cross the BBB. However, in vivo imaging
was not reported; hence, the applicability of 1.2m for in vivo imaging cannot be predicted
without further research.
Myelin is another biomarker for various neurodegenerative diseases including multiple
sclerosis, leukodystrophies, and schizophrenia because these neuropathological disorders cause
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either the degradation of myelin or the formation of defective myelin. Wang and co-workers
reported myelin-targeted contrast agent 1.2n (Figure 1.2).38,39 Contrast agent 1.2n contains a
coumarine derivative as the targeting unit conjugated to GdIIIDOTA, and this agent has a
relaxivity of 5.2 mM–1s–1 (9.4 T, 21 °C, and water). Ex vivo T1 mapping of mouse brains
incubated with 1.2n demonstrated the specificity of 1.2n for myelin.38 Subsequent in vivo studies
were carried out with intracerebroventricular infusions (~1 mg (1.14 μmol)/kg) because of the
poor BBB penetration of 1.2n. These studies demonstrated the specificity for myelin and the
ability of 1.2n to highlight demyelination with T1 mapping at 9.4 T.39 However, conventional
MR imaging was not reported with this agent, which likely was due to low sensitivity that needs
to be improved for clinical translations of 1.2n.
While monomeric agents are desirable because of their low molecular weight, in general,
studies of monomeric targeted agents reveal the need for biomarkers with high local
concentrations or for the use of large doses of contrast agents to achieve enhancement of targets
due to the low sensitivity of these agents. Therefore, it is essential to increase the sensitivity of
target-specific agents to image biomarkers with relatively low expression levels.
Multimeric target-specific contrast agents
Compared to monomeric agents, multimeric contrast agents can be used to image
biomarkers that have relatively low expression levels. Also, the blood circulation of multimeric
contrast agents tends to be longer than that of monomeric agents because the large size of
multimeric agents prevents rapid clearance via the kidneys; hence, multimeric agents often have
a longer time to interact with targets. Furthermore, high molecular weights result in slow
tumbling rates that increase relaxivity, and multimeric targeted contrast agents contain up to
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thousands of contrast-enhancing units and targeting moieties that also increase relaxivity. The
long circulation times and high relaxivities of multimeric agents enable the use of smaller doses
than monomeric agents for in vivo imaging.
Fibrin-targeted agent 1.4a (Figure 1.4) contains four GdIIIDOTA complexes conjugated
to an 11-amino-acid fibrin-targeting peptide. The relaxivity of this tetrameric contrast agent is
10.1 mM–1s–1 per GdIII ion in the absence of fibrin and increases to 17.8 mM–1s–1 per GdIII ion
upon binding to fibrin (1.41 T, 37 °C, and Tris buffered saline (TBS)).40 The effectiveness of
1.4a as a targeted contrast agent in vivo was demonstrated by imaging pulmonary emboli and
cerebral venous sinus thrombosis.41,42 Both studies were performed using swine models
containing engineered human blood clots, and contrast enhancement was reported at 1.5 T after
intravenous injection of 4 µmol/kg of 1.4a. These studies reveal the specificity of 1.4a for fibrin
and the applicability of 1.4a to the detection of fibrin-associated diseases in vivo with low doses.
A structurally similar agent to 1.4a is collagen-targeted contrast agent 1.4b (Figure 1.4).
Agent 1.4b was synthesized by conjugating three GdIIIDTPA complexes to a 16-amino-acid
peptide.43 Contrast agent 1.4b has a relaxivity of 16.1 mM–1s–1 per GdIII ion (1.41 T, 37 °C, and
PBS) or 5.4 mM–1s–1 per GdIII ion (4.7 T, 25 °C, and PBS). In vivo imaging with 1.4b (tail-vein
injection of 0.025 mmol/kg) in mouse models enabled specific imaging of myocardial fibrosis at
4.7 T.43,44 The higher dose used for 1.4b relative to 1.4a, is likely necessary due to the large
amounts of collagen present in many organs and low relaxivity reported for 1.4b at 4.7 T field
strength. With agents 1.4a and 1.4b, three or four GdIII-containing units were conjugated to the
targeting peptide via functional groups present in the amino acid side chains resulting in
increased efficiency.
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To increase relaxivity by increasing GdIII-loading, macromolecules including polymers,
dendrimers, nanoparticles, and liposomes are used.45–60 These macromolecules act as carriers to
transport large numbers of contrast agents and targeting moieties. The expectation with this
method is that contrast enhancement will be observed even if only a small number of target
molecules are labeled. Conjugation of several GdIII-containing complexes and targeting moieties
to poly(L-glutamic acid)cystamine or N-(2-hydroxypropyl)methacrylamide produced contrast
agents 1.4c and 1.4d (Figure 1.4) for targeting integrins.45,46 Agent 1.4c has a relaxivity of 9.7
mM–1s–1 per GdIII ion (3 T and water) and 1.4d has a relaxivity of 20.6 mM–1s–1 per GdIII ion (1.5
T and water). Both agents effectively bind αVβ3 intergrin in vitro, and quantitative T1 mapping
demonstrated that polymers 1.4c and 1.4d interact with integrins in the tumors of xenograft mice
using tail-vein injections of 5 µmol GdIII/kg and 0.03 mmol GdIII/kg, respectively. However, a
contrast enhancement was not observed with 1.4c or 1.4d, which likely was due to insufficient
loading of GdIII-containing complexes onto the polymers.45,46
Another type of macromolecular targeting agent uses proteins as scaffolds for targeting
moieties and GdIII-containing chelates. Maleylated bovine serum albumin conjugated to
GdIIIDOTA, 1.4e, was studied as a macrophage-scavenger-receptor-targeted contrast agent in
vitro.47 The maleyl groups acted as the targeting moieties and up to 22 Gd III-chelates were
linked to the protein. The relaxivity of 1.4e is 29.1 mM–1s–1 per GdIII ion (0.61 T, 25 °C, and
water at pH 7), and in vitro cell imaging demonstrated increased contrast for macrophages after
incubation with 1.4e.
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Figure 1.4. Multimeric targeted contrast agents synthesized using the conjugation strategy.
Contrast agents 1.4i, 1.4j, 1.4l, 1.4p, and 1.4r were adapted with permission from references
56, 58, 60, 66. Copyright 2010 American Chemical Society; and 64. Copyright 2010 WileyVCH verlag GmbH & Co. KGaA, Weinheim, respectively.
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Dendrimers are also used as carriers for multimeric agents. Polyamidoamine (PAMAM)
dendrimers are widely used as a macromolecular delivery system because they can be
functionalized easily and are biocompatible.48–50 In vivo imaging using agents 1.4f and 1.4g
composed of folic acid and GdIII-containing chelates conjugated to PAMAM dendrimers enabled
contrast enhancement of human epidermoid carcinomas in xenograft mice.49,50 The relaxivity of
these contrast agents is higher than monomeric agents, for example 64.88 mM–1s–1 per GdIII ion
(3 T and water) for 1.4f and 26.0 mM–1s–1 per GdIII ion (2 T and 20 °C) for 1.4g. These high
relaxivities enable low-dose imaging (tail-vein injections of 0.05 mmol GdIII/kg and 0.029 mmol
GdIII/kg for 1.4f and 1.4g, respectively).
Nanoparticles and liposomes that contain GdIII chelates are other classes of multimeric
targeted contrast agents. These systems enable the incorporation of different types of imaging,
therapeutic, and targeting agents to the same carrier without great synthetic burden. Tens to
thousands of GdIII or MnII ions have been loaded into nanoparticles for use as targeted contrast
agents for in vitro and in vivo studies.54,56,57 Lanza and co-workers reported integrin-targeted
contrast agents for tumor imaging using GdIII-containing nanoparticles.54,55 These nanoparticles,
1.4h, containing an αVβ3 integrin antagonist and GdIIIDTPA, were used to visualize early tumor
angiogenesis in xenograft mice using intravenous injections of 0.5 mL/kg (~0.03 nmol
particles/kg or 2.7 µmol GdIII/kg based on data in [54]). Each nanoparticle contained ~90,000
GdIII ions with a relaxivity of 1,800,000 mM–1s–1 per particle (~20 mM–1s–1 per GdIII ion, 0.47 T,
and 40 °C). Nanoparticle 1.4h produced a 173% contrast enhancement in melanoma xenografts
at 1.5 T.54 Lu and co-workers recently reported a nanoglobular system 1.4i (Figure 1.4)
containing the decapeptide CLT1 and GdIIIDOTA to target fibrin–fibronectin.56 The generation 3
nanoglobular system with a molecular relaxivity of 353 mM–1s–1 (8.2 mM–1s–1 per GdIII ion) (3
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T, 25 °C, and water) was used for in vivo imaging of tumor-bearing mice. A tail-vein injection of
0.03 mmol GdIII/kg of 1.4i produced image enhancement in the area of the tumor (Figure 1.5).
The nanoparticles were excreted via the renal pathway, which is important for the translation of
these contrast agents into clinical applications.

Figure 1.5. Representative in vivo images of targeted contrast agents: contrast enhancement
of fibronectin–fibrin complex in tumor tissues using multimeric conjugated contrast agent
1.4i. Arrows point to tumors. Reprinted with permission from reference 56. Copyright 2010
American Chemical Society.

Although, nanoparticles are potential carriers to increase the local concentration of
contrast agent at sites of interest, maintaining a size smaller than the renal excretion threshold
(~8 nm) and a high relaxivity is needed to enable the clinical application of these agents. To
achieve high relaxivity with nanoparticles, attachment of GdIII-containing chelates to the surface
of nanoparticles is more desirable than encapsulation57 because encapsulation decreases
relaxivity of nanoparticles. For example, GdIIIDOTA encapsulated in chitosan nanoparticles 1.4j
(Figure 1.4) and GdIIIDTPA encapsulated in liposomes 1.4k have lower relaxivities (1.04 mM–
1 –1

s per GdIII ion, 0.47 T, and 40 °C for 1.4k) than GdIIIDOTA and GdIIIDTPA, respectively.58,59

These low relaxivities resulted from the reduced accessibility of water molecules to the GdIII ions
due to the encapsulation inside of the hydrophobic nanosystems. Attaching Gd III-containing
chelates on particle surfaces enables facile access of water molecules to Gd III ions; however,
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attaching a large number of GdIII-containing chelates on the nanoparticle surface increases the
risk of leaching GdIII ions.
Because of the toxicity of unchelated GdIII ions, several research groups have studied
MnII-containing nanosystems for targeted imaging.60,61 Although, MnII (spin 5/2) has a lower
relaxivity than GdIII (spin 7/2), nanosystems with large MnII loadings can produce contrast
enhancement of targets. Lu and co-workers reported a nanoglobular system 1.4l (Figure 1.4) that
contained the fibrin-targeted decapeptide CLT1 and MnIIDOTA monoamide.60 This MnII
nanosystem has a relaxivity of 3.13 mM–1s–1 per MnII ion and 131 mM–1s–1 per nanoglobule (3 T
and room temperature). In vivo imaging of breast carcinoma xenograft mice that were injected
(tail-vein) with 0.03 mmol MnII/kg of 1.4l produced contrast enhancement of tumor with respect
to non-targeted controls, and the contrast agents were excreted through the kidneys. Manganese
oxide nanocolloidal systems also were reported to target fibrin.61 MnII oxide nanocolloide 1.4m
and MnII oleate nanocolloide 1.4n both labeled fibrin clots in vitro. The relaxivities of 1.4m and
1.4n were 4.1 and 14.6 mM–1s–1 per MnII ion (91,127 and 423,420 mM–1s–1 per particle at 3T, 25
°C), respectively. These high relaxivity values and in vitro studies suggest that MnII oxide
nanocolloides could be useful for in vivo fibrin detection.
Superparamagnetic target-specific contrast agents using the conjugation strategy
Superparamagnetic iron oxide (SPIO) nanoparticles coated with polymers are another
class of contrast agents for MRI. These agents enhance the contrast of images by decreasing
signal intensity in T2- and T2*-weighted imaging and, consequently, darkening the target area
relative to surrounding tissues. Although, the darkening effect (negative contrast) is not ideal for
anatomical imaging, many SPIO-based target-specific contrast agents are reported with T2-
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weighted imaging because they can be used for target detection in post-injection images when
compared to pre-injection images. Additionally, SPIO-based images can be converted to positive
imaging agents using different pulse sequences and post-processing positive-contrast
techniques.62 Although, these new positive imaging techniques with SPIO nanoparticles have
been reported with cell labeling and tracking studies, we have limited our discussion on SPIObased target-specific contrast agents in this section to conventional T2- or T2*-weighted imaging.
SPIO nanoparticles are used in MRI because of the biocompatibility of iron oxide
nanoparticles and high T2 relaxivity for contrast enhancement. These biocompatible SPIO
nanoparticles are taken up by the reticuloendothelial system (RES) in cells; hence, in early
studies, SPIO nanoparticles were used to detect lesions in RES-rich organs including the liver,
spleen, and lymph nodes without the use of a conjugated targeting moiety.17 However, recent
research has focused on conjugating targeting moieties to the nanoparticle surface to achieve
selectivity to areas other than hepatic lesions. Conjugation of targeting moieties to the iron oxide
core is possible because of the polymeric coatings used to stabilize the SPIO nanoparticles.
Rajabi and Tsourkas and co-workers reported the use of targeted SPIO nanoparticles for
selective detection of tumors in vivo.63,64 The contrast agents reported by these groups target the
HER2 receptor in tumor tissues and consisted of magnetic nanoparticles modified with the
monoclonal antibody Trastuzumab, 1.4o, or with a HER2-affibody, 1.4p (Figure 1.4). To
synthesize particle 1.4o, the targeting antibody was conjugated to the nanoparticle using an
amine-containing linker incorporated into a dextran coating.63 Whereas, in particle 1.4p, the
azide–alkyne Huisgen cycloaddition (often referred to as “click” chemistry) was used to
conjugate an alkynated linker containing the HER2-targeted affibody to a polymer coating
functionalized with azides.64 Agent 1.4o enhanced the tumor regions in mouse models relative to
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surrounding tissues with 30 µmol/kg (tail-vein injections). For agent 1.4p, a 10 mg (0.18 mmol)
Fe/kg dose was used (retro-orbital injection) to enhance contrast of tumors (Figure 1.6). Iron
oxide nanoparticles conjugated with urokinase-type plasminogen activator (uPA) peptide, 1.4q,
used carboxylates on the polymer coating to conjugate with targeting moieties.65 The uPA
peptide was engineered to contain an amine that enables conjugation with nanoparticles via
amide linkages. Contrast agent 1.4q has relaxivity (T2) value of 124 mM–1s–1 (3 T) and targets
uPA receptors that are over-expressed in tumors. In vivo imaging with intravenous injections of
1.4q at 3 T using mammary carcinoma bearing mouse models demonstrated enhanced contrast in
the tumor region, but contrast enhancement within the tumor was heterogeneous. This
heterogeneous distribution of 1.4q in tumor tissue and the resultant decrease in signal intensity
enabled an understanding of receptor distribution in addition to tumor detection. Another cancercell-targeted SPIO-nanopartcle-based contrast agent, 1.4r (Figure 1.4), acts as a drug delivery
vehicle as well as an imaging probe.66 In this study, SPIO nanoparticles were labeled with a
monoclonal antibody, a fluorescent probe, and four anticancer drugs that release from the SPIO
nanoparticle in response to changes in pH. Although, in vivo imaging was not performed, in vitro
studies of this potential theranostic agent using human colon cancer cells (LS174T) demonstrated
a reduction of T2 in cells incubated (0.03 mg/mL and 37 °C) with 1.4r (55.5 ms) with respect to
untreated control cells (117.3 ms) at 7 T.
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Figure 1.6. Representative in vivo images of targeted contrast agents: contrast enhancement of
HER2-positive tumors using conjugated SPIO nanoparticle 1.4p. Arrows point to tumors.
Adapted with permission from reference 64. Copyright 2010 Wiley-VCH Verlag GmbH &
Co. KGaA, Weinheim.

Other than tumor imaging, SPIO nanoparticles are reported to detect renal inflammations.
Thurman and co-workers reported the use of SPIO nanoparticles, 1.4s, conjugated with a
recombinant protein that targets the complement receptor type 2 in kidneys for in vivo studies of
glomerulonephritis. A dose of 10–16 mg of particles/kg enhanced contrast of the kidneys of
diseased mice and demonstrated the potential for selective visualization of renal inflammation
without the need for invasive renal biopsies.67,68
The direct conjugation of targeting moieties with contrast agents or carrier molecules
containing contrast agents is synthetically a simple approach to achieve selectivity. Therefore,
both in vitro and in vivo imaging are reported for many targeted agents synthesized with this
strategy. Monomeric targeted agents interact with or are internalized by targeted cells and can
clear from the body easily because of their small size. But, monomeric agents often have low
sensitivity. Multimeric agents that bear up to thousands of contrast-enhancing units and targeting
moieties have high relaxivities because of their large size and the number of conjugated contrast
agents. However, large size can result in difficulties in clearance. Therefore, while each class of
targeted agents has potential niche uses, multimeric agents of intermediate size that have high
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relaxivities but remain within the renal-clearance threshold likely will be the agents with more
potential for in vivo applications in the future.
Target-specific contrast agents designed with the structure-mimicking strategy
Transforming contrast agents into structural mimics of molecules that interact with
specific tissues and receptor molecules is a targeting strategy that converts contrast agents
directly into targeting moieties. However, the synthesis of contrast agents that mimic the
structure of biologically active molecules can be synthetically challenging. Several attempts to
synthesize targeted biomimetic contrast agents have been reported and include porphyrin-, highdensity-lipoprotein-, and ferritin-based agents.69–79
Porphyrins selectively accumulate in necrotic tissues and interact with neurons;69,80,81
porphyrins also form stable complexes with some metal ions and possess optical properties that
are advantageous for imaging studies. Consequently, several porphyrin-based contrast agents
have been reported for tumor targeting. MnIII-containing porphyrin–dextran system 1.7a (Figure
1.7) was used to visualize tumors in vivo. Porphyrin agent 1.7a has a relaxivity of 8.90 mM–1s–1
(4.7 T and aqueous solution) and enhances tumor contrast in mice bearing hepatoma tumors
using a 0.05 mmol MnIII/kg dose (intravenous injection).70 Another MnIII-based porphyrin, 1.7b
(Figure 1.7), was reported as a brain-tissue-specific contrast agent that is cell permeable and
labels neuronal cell bodies in the hippocampus.71 However, the introduction of contrast agent
1.7b to rat brains (0.017–0.02 µmol/kg dose) using direct injection and the long retention time
reported in brain tissues (t1/2 ≈ 10 days) suggest areas for future research with this contrast agent.
Although, MnIII-containing porphyrins have higher relaxivities than clinical contrast
agents, they have lower relaxivities than GdIII-containing porphyrins.70,72 Two GdIII-containing
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porphyrins 1.7c and 1.7d (Figure 1.7) were reported for in vivo melanoma imaging (relaxivities
of 16.3 and 31.7 mM–1s–1 at 7 T, 23 °C, and aqueous solutions for 1.7c and 1.7d
respectively).72,73 In vivo imaging of xenograft nude mice using 0.1 mmol/kg of 1.7c and 1.7d
(intravenous bolus injections) showed contrast enhancement in tumors due to specific
accumulation.72 However, GdIII-containing porphyrins are kinetically unstable in solution
because of the size disparity between the cation and porphyrin cavity.74,82 Hence, expanded
porphyrin systems, such as texaphyrins, are used to form stable complexes with GdIII. Like
porphyrins, GdIII-containing texaphyrins accumulate in tumors and enhance contrast.83 The
relaxivity of GdIII-containing texaphyrin 1.7e (Figure 1.7) is 18 mM–1s–1 (1.2 T, 25 °C, and
aqueous saline).84 Because of the specific accumulation of texaphyrins in tumors and the optical
properties of these molecules, texaphyrins are used as radiation sensitizers for tumor therapy and
as tumor-specific imaging probes.85
Another porphyrin structural mimic used as a targeted contrast agent is the copper
phthalocyanine dye Luxol fast blue MBS (LFB MBS) 1.7f (Figure 1.7). Complex 1.7f is a
histology stain for myelinated neurons that was studied as a contrast agent for MRI in ex vivo
brain tissues.81 The relaxivity of this agent is low (0.15 mM–1s–1, 4.7 T, and ethanol) partially
because the CuII ion has a spin of 3/2. Heavily myelinated regions appeared brighter in images
when stained with LFB MBS with respect to control experiments, but to attain good contrast
enhancement, similar molecules containing metals with higher spin values need to be
synthesized.
Synthetic high-density lipoprotein (HDL) nanoparticles are another class of targeted
contrast agents that mimic natural molecular entities to achieve selectivity. HDL particles are
made into contrast agents by incorporating chelated GdIII into the outer phospholipid coating or
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by loading the core of the HDL particle with iron oxide.75,76 Synthetic HDL nanoparticles 1.7g
and 1.7h (Figure 1.7) target atherosclerosis. In vivo imaging of genetically engineered
hyperlipidemic (ApoE KO) mice with tail-vein injections of 3.25 and 4.36 µmol/kg doses of 1.7g
(relaxivity (T1) of 10.4 mM–1s–1 per particle, 1.5 T, 25 °C, and water at pH 7.4) demonstrated
contrast enhancement of plaques (Figure 1.8).75 In vivo imaging of ApoE KO mice with 1.7h
(relaxivity (T2 ) of 94.2 mM–1s–1, 1.41 T, and 40 °C) also demonstrated contrast enhancement of
plaques using 30 mg (0.54 mmol) Fe/kg.76
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Figure 1.7. Targeted contrast agents synthesized using the structure mimicking strategy.
Contrast agents 1.7g, 1.7h, and 1.7k were adapted with permission from references 75, 78,
and 86. Copyright 2004 and 2008 American Chemical Society.

Another iron-oxide-containing biomimetic used as a targeted agent is ferritin. Ferritin is a
protein that stores iron and regulates levels of iron in the body. Consequently, endogenous
ferritin can be used to recognize some ferritin-related diseases using MRI.77 Thus, ferritin
provides a template to generate SPIO-based contrast agent mimics. Recombinant human H chain
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ferritin, 1.7i, was used in vitro as a macrophage-targeted contrast agent, and these studies showed
selective uptake of 1.7i by macrophages (incubated with 165 µg (3 µmol) Fe/mL of 1.7i)
resulting in contrast enhancement at 1.5 T.78 In another study, cationic ferritin 1.7j was used as a
basement-membrane-selective contrast agent to detect glomerulosclerosis.79 Both ex vivo and in
vivo imaging using 1.7j in rat models at 11.7 T detected disruptions of basement membranes;
however, five intravenous injections of a relatively high dose (~5 mg (0.089 mmol) Fe/kg) was
required to detect cationic ferritin accumulation in glomeruli in vivo: this high dose is a challenge
for translation into clinical applications.

Figure 1.8. Representative in vivo images of targeted contrast agents: contrast enhancement
of atherosclerotic plaques using high-density lipoprotein mimic 1.7g. Arrows point to
abdominal aorta. Adapted with permission from reference 75. Copyright 2004 American
Chemical Society.
Recently, Yang and co-workers reported engineered proteins that chelate GdIII ions to
produce stable high relaxivity contrast agents for MRI.86 An example is a contrast agent
containing an engineered cell adhesion protein 1.7k (Figure 1.7) with a domain to chelate GdIII
ions. Agent 1.7k has a relaxivity of 117 mM–1s–1 (1.5 T) enabling doses as low as 2.4 µmol
GdIII/kg for contrast-enhanced imaging. Using this approach, endogenous proteins can be
mimicked to synthesize targeted contrast agents with higher efficiency.
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While the structure-mimicking strategy enables the use of endogenous interactions to
deliver agents, synthesizing targeted agents with the structure-mimicking strategy is challenging
and not generalizable like the conjugation strategy. Therefore, the scope of targets and number of
examples are limited relative to agents synthesized with the conjugation strategy. Some of these
agents have high relaxivities and enhance contrast in vivo; however, more research is needed in
this area to improve current mimetic agents and to find new biomimetics that form stable
paramagnetic complexes and are specific for various tissues and diseases.
Summary
Targeted contrast agents enable the visualization of structural changes in organs or the
expression of biological molecules, and these agents have the potential to aid in the diagnosis of
diseases at early stages. In general, targeting ability is achieved by conjugating a targeting
moiety to a contrast agent or by mimicking the structural features of targeting moieties with
contrast agents. A large number of targeted agents have been synthesized with the conjugation
strategy, and while conjugation of a single contrast-enhancing unit per targeting moiety enables
selective imaging in the presence of high local concentrations of targets, many such contrast
agents suffer from low sensitivity and require large doses to achieve contrast enhancement. The
use of multiple contrast-enhancing units in multimeric agents overcomes the limitation of
sensitivity, but the large size of multimeric agents can cause difficulties with excretion. Synthesis
of macromolecules smaller than the renal excretion threshold is a strategy to avoid this problem,
but this strategy also influences relaxivity. Also, polydispersity of these systems can lead to
difficulties with reproducibility. Relatively few examples of the mimicking strategy are reported
for the design of targeted contrast agents because of the limited availability of biomimetics that
form stable complexes with paramagnetic cations; however, recent advances in nanochemistry
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and biotechnology will likely lead to more opportunities for mimicking biologically important
structures with contrast agents.
Except for one or two target-specific contrast agents that are clinically approved (MS325) or in clinical-trials (texaphyrins), the majority of target-specific agents are in pre-clinical
levels of research; however, successful in vivo imaging was reported with many pre-clinical
studies, and these results shine positive light onto the future of the field. An area of where extra
attention to detail will likely aid the field is the inclusion of as many experimental details as
possible: the direct comparison of different studies is difficult because the conditions used for
relaxivity measurements and imaging experiments are different (Table 1.1), and improper
comparisons could lead to misinterpretations of the efficiency of one agent compared to another.
Finally, improvements to the selectivity, sensitivity, and biocompatibility of target-specific
agents and the selection of new molecular targets using both the conjugation and mimicking
strategies will likely enable translation into clinical applications for MRI.
Focus and layout of this thesis
The focus of the research described in this thesis is the exploration of the utility of GdIIIcontaining complexes to achieve targeted imaging with MRI. The two targets that were selected
were myelin and β-amyloid plaques, which are important markers for detection of neurological
disease as described earlier in this chapter. The ability to detect neurological disease without
ambiguity is important for clinical imaging where early detection is essential for better treatment,
and also for the advancement of related research. The findings of the research in this thesis
would be mostly important for pre-clinical research related to neurological disease because these
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studies lead to ex vivo and in vitro targeted imaging of myelin and β-amyloid aggregates,
respectively.
To achieve the target specificity with GdIII-containing complexes, both the conjugation
and structure mimicking synthetic strategies that introduced previously in this chapter were used.
The GdIII-containing complex that was used to achieve the targeting of β-amyloid aggregates was
synthesized using conjugation strategy, and the GdIII-containing complexes for targeting myelin
were synthesized using structure mimicking strategy. In Chapter 2, the design and synthesis of
each metal complex is detailed including a discussion of the features of the new designed
complexes that are important to achieve target specificity. In Chapters 3 and 4, the experiments
are described that establish the ability of these complexes to act as target-specific contrast agents.
In Chapter 5, the results reported in Chapters 2–4 are summarized in the context of other
reported contrast agents and includes a discussion of suggested future directions for this research.
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CHAPTER 2. Ligand design and synthesis
Introduction
Target-specific metal complexes can be achieved using two synthetic strategies, either
conjugation or structure mimicking, as described in Chapter 1. To obtain efficient targeting and
imaging, these metal complexes need to fulfill several requirements regardless of the synthetic
strategy that is being used, including (1) enabling interaction with the target, (2) maintaining
kinetic stability under the conditions of imaging, (3) having no interference of function between
the targeting and imaging components, and (4) being synthetically feasible. Thus, addressing
these requirements is an essential step in ligand design to achieve efficient target-specific
contrast agents. The metal complexes presented in this thesis as contrast agents for magnetic
resonance imaging (MRI) were designed to fulfill these four requirements. The following
sections describe the design, synthesis, and the characterization of the metal complexes.
Design and synthesis of a β-amyloid-targeted metal complex.
The β-amyloid-targeted metal complex 2.1 was designed to be synthesized using the
conjugation strategy, specifically by conjugating a small molecule known to have affinity for amyloid plaques to a derivative of a GdIII-based contrast agent. The -amyloid-plaque-selective
small molecule that was chosen is curcumin, 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6heptadiene-3,5-dione (Figure 2.1a). Curcumin is a compound found in the rhizomes of the plant
Curcuma longa, and it is a relatively hydrophobic, fluorescent molecule that is non-toxic at gram
dosages.87 Curcumin is known to interact with amyloid fibrils, and the planar hydrophobic
aromatic structure of the molecule is considered to be the key feature for its interaction with βamyloid fibrils.88
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The β-pleated structure of aggregated amyloid protein allows small planar hydrophobic
molecules to intercalate among β-pleated
sheets and aromatic residues in the protein,
leading to specific retention of these
molecules in amyloid plaques. Therefore,
curcumin is a good candidate for a targeting
moiety for β-amyloid aggregates with its
Figure 2.1. Chemical structures of (a) curcumin
and (b) GdIIIDTPA-BnSCN.

planar,

hydrophobic,

and

non-toxic

properties. Furthermore, synthetic curcumin

is commercially available, and there are several functional groups found in curcumin including
phenols and a β-ketoenol that can be used for conjugation reactions.
The contrast agent that was chosen for the conjugation is a GdIII-containing complex of
diethylenetriaminepentaacetic acid functionalized with an isothiocyanate group (Gd IIIDTPABnSCN) (Figure 2.1b). GdIIIDTPA is a clinically approved contrast agent for MRI, and the
isothiocyanate group imparts the ability to conjugate to various nucleophilic functionalities.
Furthermore, benzyl-isothiocyanate-containing DTPA is commercially available.
Initial design of the metal conjugate included a direct conjugation of the isothiocyanate
group to the activated α-carbon of the β-ketoenol. To synthesize the conjugate, the phenols were
first protected with benzoyl chloride and then two different sets of reaction conditions were tried
to accomplish the desired reaction. The first attempt included the reaction of benzoyl-protected
curcumin with GdIIIDTPA-BnSCN in dimethylsulfoxide in the presence of KOH following
published procedures for the conjugation of similar functional groups.89 The second attempt
included the reaction of benzoyl-protected curcumin with sodium ethoxide to form the sodium
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salt of enolate of 2.1a and subsequent reaction of with GdIIIDTPA-BnSCN in pyridine. These
reaction conditions did not result in the desired conjugate based on mass spectrometric analysis.
The reason that avoided the occurrence of the reaction assumed to be the steric hindrance caused
by DTPA molecule. Because direct conjugation of the curcumin molecule to the isothiocyante
group in GdIIIDTPA-BnSCN was not successful, the targeted complex was redesigned by
introducing an amine containing arm to the curcumin molecule.
The rationale behind the introduction of an amine linker included facilitating the reaction
of GdIIIDTPA-BnSCN with curcumin and incorporating space between the targeting moiety and
the imaging unit to avoid potential interference of function. The amine linker was synthesized
using a published procedure90 and was introduced to one of the phenol groups using sodium
methoxide in methanol. The isolated amine-linker-containing curcumin was conjugated to
GdIIIDTPA-BnSCN in the presence of diisopropylethylamine (DIEA) in aqueous acetonitrile
(Scheme 2.1).

Scheme 2.1. Synthetic route to β-amyloid-targeted curcumin-conjugated GdIII-containing
complex 2.1.
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Design and synthesis of myelin-targeted metal complexes
Myelin-targeted metal complexes were designed to be synthesized using the structure
mimicking strategy. A known myelin-specific histology stain, luxol fast blue MBS (LFB MBS),
was selected as the template molecule (Figure 2.2). LFB MBS was found to be a stain for
myelin in 1953 by Klüver and Barrera
based on the knowledge that porphin
derivatives are able to bind with myelin
and that the phthalocyanine ring is similar
in structure to porphyrins.91 Although it is
Figure 2.2. Structure of LFB MBS stain

known that LFB MBS is capable of

staining myelin, the site of interaction and nature of the interaction is unknown. However,
several potential sites of interaction have been suggested:

phospholipids, neurokeratin,

proteolipid proteins, lipoproteins, and myelin basic proteins.81 From these potential sites, the
acid–base type of interaction between LFB MBS and myelin basic protein is more accepted due
to the removal of ditolylguanidinium cation from stain upon interaction.92 The planar non-polar
structure of the LFB MBS is assume to facilitate the diffusion of LFB MBS into the myelinated
regions in tissue, thus facilitating the interaction between the sulfonate groups of LFB MBS and
the basic proteins containing cationic amino acids such as arginine. Despite functional
knowledge of the myelinLFB MBS interaction being limited, LFB MBS was used as the
template molecule to design a myelin-targeted contrast agent in this research because its structure
includes a macrocyclic ligand coordinated to a metal, and this motif is amenable to adaptation
into a contrast agent for MRI. The texaphyrin ligand (Figure 2.3) was selected to design a
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complex containing the GdIII ion by mimicking the structural features of the phthalocyanine
ligand of LFB MBS. Of the chelating ligands for trivalent lanthanide cations that have been
reported in the literature, the texaphyrin
macrocycle shows a good potential to
mimic the LFB MBS ligand fulfilling
the requirements mentioned at the
beginning of this chapter, namely, the
ability to form a stable complex with
Figure 2.3. General structure of texaphyrin
ligands. R can include a variety of different
functional groups.

GdIII, good relaxivity that is essential
for imaging, and synthetic feasibility.

Structural similarities of phthalocyanine and texaphyrins include 22π Hückel aromatic systems,
pyrrolic nitrogen donor atoms, and a planar macrocyclic structure. Additionally, the potential to
introduce functional groups to the side chains of texaphyrins allows further mimicking of the
LFB MBS structure. Using the texaphyrin ligand core, six different paramagnetic metal
complexes, 2.2–2.7, were designed to study the effect of charge and acid functional groups on
myelin binding (Figure 2.4).
The functional groups incorporated in these designed molecules include esters,
sulfonates, and carboxylates. All these functional groups have oxygen donor atoms, and
sulfonates and carboxylates carry negative charges. Sulfonates were chosen to exactly mimic the
functional group in LFB MBS, and carboxylates were chosen to investigate if the acid group
needs to be sulfonates. Methyl esters were chosen to study the need for acid functional groups.
Additionally, the methyl ester containing texaphyrin is an intermediate in the synthesis of the
carboxylate-containing texaphyrin. Sessler and coworkers have intensively studied texaphyrin
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complexes with different functional groups including alcohol, ether, ethyleneglycol, amine, and
chloro groups;93–95 however, functional groups of complexes 2.2–2.7 have not been reported
previously with the texaphyrin motif.

Figure 2.4. Target texaphyrin complexes

The overall charge of complex 2.2 is +2, and it does not have acidic functional groups;
thus, it was designed to use as a control if negative charge or acidic functional groups are crucial
for myelin-specific interactions. Complexes 2.4–2.6 have sulfonic acid groups and charges of 0,
–1, and –2, respectively, and they were designed to use to study the necessity of sulfonate groups
and the effect of the number of sulfonate groups on interaction with myelin. Complexes 2.3 and
2.7 have carboxylate groups with charges of 0 and –2, respectively, representing the carboxylate
analogues of sulfonate texaphyrin complexes. All six of these complexes were designed to study
with ex vivo mouse brain samples to investigate the important features for effective myelinspecific binding. Syntheses of metal complexes 2.22.6 were achieved as outlined in Scheme
2.2.
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Scheme 2.2. Synthetic route to GdIII-containing texaphyrin complexes 2.22.6.

The synthesis of complex 2.7 was not confirmed by any characterization technique—including
mass spectrometry, NMR spectroscopy, and UV–vis spectroscopy—despite the employment of a
variety of synthetic conditions (Table 2.1). Hence, the synthesis of complex 2.7 was not
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achieved. However, this set back did not affect the studies of myelin binding because complexes
2.22.6 contain all of the necessary variables to complete the planned studies.
Table 2.1. Synthetic conditions attempted toward the synthesis of complex 2.7
Starting material

Reaction type and
reaction conditions
metallation
Gd(OAc)3·4H2O,
triethylamine, methanol,
air, reflux

Sapponification of esters
1. LiOH, THF, H2O
2. NaOH, MeOH, H2O
3. NH4OH (aq)
4. Me3SnOH, C2H4Cl2, 80 °C
5. NaOSi(CH3)3, THF
6. DOWEX 8×50W-100, H2O,
reflux

Observations
A precipitate formed from the
reaction mixture.
UV–vis spectrum did not show
the formation of metallated
complex.

Conditions 1 and 2 resulted in
depletion of metal-complexspecific absorptions at 474 and
740 nm. The resulting residue
was insoluble in water and other
common organic solvents. With
conditions 3–6 the metalcomplex-specific
absorptions
were present. However, they also
produced an insoluble residue
and the only identifiable peak in
mass spectra was starting
material.
Oxidation of alcohols
1. Depletion of metal-complex1. Pyridiniumdichlorochromate, specific absorptions at 474 and
dimethylformamide
740 nm
2. 2,2,6,6-tetramethylpiperidine- 2.
Alcohols
oxidized
to
1-oxyl, PhI(OAc)2, H2O, aldehydes
acetonitrile
3. Depletion of metal complex
3. KMnO4, NaOH
specific
absorption
and
appearance of a new peak in the
300–400 nm regions.
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Experimental procedures for GdIII-containing target-specific metal complexes.
Commercially available chemicals were of reagent-grade purity or better and were used
without purification unless otherwise noted. Water was purified using a PURELAB Ultra Mk2
water purification system (ELGA). Compounds 2.1c,90 2.1f,19 2.2b,96 2.2c,95 2.3c,94 and 2.2f95
were synthesized using previously published procedures. Compounds 2.3a and 2.3b were
synthesized following a similar procedure to reference 97. Compound 2.2e was synthesized
following the procedure in reference 98 with some modifications to purification.
Analytical thin-layer chromatography (TLC) was carried out on ASTM TLC plates
precoated with silica gel 60 F254 (250 μm layer thickness). Visualization of TLC was
accomplished using a UV lamp followed by charring with potassium permanganate stain (3 g
KMnO4, 20 g K2CO3, 5 mL 5% w/v aqueous NaOH, 300 mL H2O) or by charring with ceric
ammonium molybdate stain (4 g cerium(IV) sulfate hydrate complex with sulfuric acid, 100 g
ammonium molybdate tetrahydrate, 900 mL H2O, 100 mL concentrated H2SO4).

Flash

chromatography was performed using silica gel 60, 230–400 mesh (EMD Chemicals) or
aluminum oxide, activated, acidic, Brockmann I, standard grade, ~150 mesh, 58 Å (Sigma
Aldrich). Preparative reverse-phase chromatography was performed using RP-tC18 SPE SepPak columns (Waters) and a high-performance liquid chromatography (HPLC) system
(Shimadzu) equipped with a C18 column (Restek International, Viva C18, 5 μm, 250 × 10.0
mm). Analytical HPLC analyses were performed with a C18 column (Restek International, Viva
C18, 5 μm, 250 ×4.6 mm). Both preparative and analytical HPLC used a binary gradient method
(pump A: water, pump B: acetonitrile; 5% B for 5 min, 5–30% B over 1 min, 30% B for 10 min,
30–95% B over 1 min, 95% B for 2 min) for complex 2.1, and (pump A: water, pump B:
acetonitrile; 5% B for 5 min, 5–95% B over 7 min, 95% B for 1 min, 95–5% B over 1 min) for
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complexes 2.2–2.6. The flow rates used for preparative and analytical columns were 5 and 1
mL/min, respectively. Detection was carried out with a photodiode array detector and
fluorescence detector (λex = 395 nm, and λem = 521 nm).
1

H NMR spectra were obtained using a Varian Mercury 400 (400 MHz) spectrometer,

Agilent 400 (400 MHz), Varian 500 (500 MHz), or Agilent 600 (600 MHz) spectrometers, and
13

C NMR spectra were obtained using a Varian Mercury 400 (101 MHz), Agilent 400 (101

MHz), Varian 500 (126 MHz), or Agilent 600 (151 MHz) spectrometers. Chemical shifts are
reported relative to residual solvent signals unless otherwise noted (CDCl3: 1H: δ 7.27,
77.16; dimethylsulfoxide-d6: 1H: 2.50,

13

C: 39.52; D2O: 1H: 4.79,

13

13

C: δ

C: 49.00 for an internal

standard of methanol-d4 or 39.52 for an internal standard of dimethyl sulfoxide-d6; CD3OD/D2O
mixture, 1H: 4.79,

13

C: 49.00). NMR data are assumed to be first order, and the apparent

multiplicity is reported as “s” = singlet, “d” = doublet, “dd” = doublet of doublets, “t” = triplet,
“q” = quartet, “m” = multiplet, or “brs” = broad singlet. Italicized elements are those that are
responsible for the chemical shifts. High-resolution electrospray ionization mass spectra
(HRESIMS) were obtained on an electrospray time-of-flight high-resolution Waters Micromass
LCT Premier XE mass spectrometer. UVvis spectra were obtained on Shimadzu UVmini-1240
UVvis spectrophotometer. Data are reported as UV–vis (solvent) max, nm (ε). Abbreviations:
max is the wavelength of maximum absorption in nanometers; ε is the molar absorption
coefficient; and sh is the shoulder. Fluorescence spectra were obtained using a HORIBA Jobin
Yvon Fluoromax-4 spectrofluorometer.
Sonication was performed using a FS60H sonicator (Fisher Scientific). Centrifugation
was performed using a mini-centrifuge (05-090-100, Fisher Scientific) at 6600 rpm or
Centrific™ Centrifuge at 7000 rpm (04-978-50, Fisher Scientific). Vortexing was done using a
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vortex mixer (Fisher Scientific). Freeze drying was performed using a Freezone 2.5 freeze dryer
(LABCONCO). Elemental analyses were performed by Midwest Microlab LLC, Indianapolis,
Indiana, USA.

β-amyloid-targeted metal complex
tert-Butyl-2-(2-(4-((1E,4Z,6E)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-3-oxohepta-1,4,6trienyl)-2-methoxyphenoxy)acetamido)ethylcarbamate (2.1d):
To a solution of commercially available curcumin, 2.1a, (205 mg, 0.557 mmol, 1 equiv)
in anhydrous methanol (7 mL) at 50 °C was added a solution of sodium methoxide (0.81 mmol,
0.54 M, 1.5 equiv) in anhydrous methanol (1.5 mL) dropwise over a period of 20 min under Ar.
The resulting reaction mixture was stirred for 40 min at 50 °C under Ar. A mixture of amine
linker 2.1c (323 mg, 1.36 mmol, 2.5 equiv) and KI (186 mg, 1.12 mmol, 2 equiv) in anhydrous
methanol (1 mL) was added to the reaction mixture dropwise over 15 min. Anhydrous toluene (3
mL) was added, and the resulting reaction mixture was stirred at 80 °C under Ar for 22 h in the
dark. Volatiles were removed under reduced pressure, and the resulting solid was purified using
silica gel column chromatography (stepwise gradient of 2:3→4:1→1:0 ethyl acetate/hexanes) to
yield 2.1d (0.11 g, 34%) as an orange oil. 1H NMR (400 MHz, CDCl3, δ): 1.43 (s, CH3, 9H),
3.18–3.58 (m, CH2, 4H), 3.95 (s, CH3, 6H), 4.57 (s, CH2, 2H), 4.87 (brs, NH, 1H), 5.83 (s, CH,
1H), 5.96 (brs, OH, 1H), 6.49 (d, J = 15.98 Hz, CH, 1H), 6.52 (d, J = 15.58 Hz, CH, 1H), 6.80–
7.19 (m, ArH, 6H), 7.22 (brs, NH, 1H), 7.59 (d, J = 15.58 Hz, CH, 1H), 7.61 (d, J = 15.98 Hz,
CH, 1H), 16.01 (brs, OH, 1H);

13

C NMR (101 MHz, CDCl3, δ): 28.5 (CH3), 39.6 (CH2), 40.6

(CH2), 56.1 (CH3), 56.2 (CH3), 69.2 (CH2), 79.8, 101.6 (CH), 109.8 (CH), 110.9 (CH), 114.9
(CH), 115.1 (CH), 121.9 (CH), 122.2 (CH), 123.2 (CH), 123.3 (CH), 127.7, 130.3, 139.8 (CH),
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141.1 (CH), 147.0, 148.2, 148.8, 149.9, 156.5, 169.1, 182.6, 184.2; TLC: Rf = 0.23 (4:1
ethylacetate/hexanes); HRESIMS (m/z): [M + H]+calcd for C30H37N2O9, 569.2499; found,
569.2504.
Curcumin-conjugated GdIIIDTPA complex (2.1):
Compound 2.1d (34 mg, 0.060 mmol) was added to a solution of HCl (3 M) in ethyl
acetate (2.5 mL), and the resulting mixture was stirred at ambient temperature for 30 min.
Solvents were removed under reduced pressure, and the product was triturated with diethyl ether
(2 × 3 mL) to obtain a brown solid (26 mg, 0.056 mmol, 1 equiv) that was dissolved in water
(0.2 mL). To the resulting solution was added a solution of DIEA (39 µL, 0.22 mmol, 4 equiv) in
acetonitrile (0.2 mL) dropwise over 5 min while stirring. At the end of the addition, water (0.2
mL) was added to the reaction mixture followed by complex 2.1f (55 mg, 0.079 mmol, 1.4
equiv) as a solid in 4 equal portions. Upon complete addition of 2.1f, water (1.1 mL) was added
to the reaction mixture that was subsequently sonicated (1 min). The reaction mixture was
stirred in the dark at ambient temperature for 6.5 h then purified by reverse-phase
chromatography using RP-tC18 SPE Sep-Pak (stepwise gradient of 3:7→1:1 acetonitrile/water)
followed by HPLC. Volatiles were removed under reduced pressure, and the resulting residue
was dissolved in water (1 mL) and freeze dried to obtain 2.1 (0.010 g, 16%) as a fluffy yellow
powder. HRESIMS (m/z): [M]2– calcd for C47H51N6O17SGd, 579.1129; found, 579.1102. HPLC
chromatograms on page 115 in Appendix B.

43

Myelin-targeted metal complexes
Benzyl 4-ethyl-3,5-dimethyl-1H-pyrrole-2-carboxylate (2.3a):
To a vigorously stirring suspension of diethylaminomalanoate hydrochloride salt (3.0 g,
14 mmol, 1 equiv) in CH2Cl2 (30 mL) was added a saturated solution of NaHCO3 (22.5 mL)
dropwise over 20 min, and stirring was continued for 20 min. The aqueous layer was decanted.
The organic layer was dried over anhydrous MgSO4, filtered, and the solvent was removed under
reduced pressure to yield 2.5 g (95%) of diethylaminomalanoate as a colorless liquid. To
refluxing glacial acetic acid (12 mL) was added a mixture of diethylaminomalanoate (2.0 g, 11
mmol, 1 equiv) and 3-ethyl-2,4-pentanedione (1.5 g, 11 mmol, 1 equiv) dropwise over 30 min.
The reaction mixture was heated at reflux for 3 h and poured into ice. The resulting precipitate
was filtered and the solvent was removed under reduced pressure to yield 1.2 g (60%) of ethyl 4ethyl-3,5-dimethyl-1H-pyrrole-2-carboxylate as an off white crystalline solid. 1H NMR (400
MHz, CDCl3, δ): 1.06 (t, J = 7.6 Hz, CH3, 3H), 1.35 (t, J = 7.2 Hz, CH3, 3H), 2.21 (s, CH3, 3H),
2.29 (s, CH3, 3H), 2.39 (q, J = 7.6 Hz, CH2, 2H), 4.30 (q, J = 7.2 Hz, CH2, 2H), 8.70 (brs, NH,
1H);

13

C NMR (101 MHz, CDCl3, δ): 10.6 (CH3), 11.5 (CH3), 14.7 (CH3), 15.5 (CH3), 17.3

(CH2), 59.7 (CH2), 116.8, 124.0, 126.9, 129.2, 161.9.
To a gradually heating (from ambient temperature to 200 °C over 2 h) solution of 4-ethyl3,5-dimethyl-1H-pyrrole-2-carboxylate (1.25 g, 6.41 mmol, 1 equiv) in benzyl alcohol (6 mL)
was added a mixture of sodium (14.8 mg, 0.641 mmol, 0.1 equiv) dissolved in benzyl alcohol
(1.2 mL) portionwise over 2 h. After the addition of sodium, the reaction mixture was stirred for
5 min at 200 °C, and the hot solution was poured into a cooled mixture of ethanol/water/glacial
acetic acid (0 °C, 1:0.75:0.01, 14.1 mL). The resulting mixture was cooled at 0 °C for 20 min.
The resulting precipitate was filtered, and washed with cold ethanol (0 °C, 2 mL). Solvent was
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removed under reduced pressure to yield 1.18 g (72%) of 2.3a as a white fluffy solid. 1H NMR
(400 MHz, CDCl3, δ): 1.05 (t, J = 7.6 Hz, CH3, 3H), 2.20 (s, CH3, 3H), 2.30 (s, CH3, 3H), 2.39
(q, J = 7.6 Hz, CH2, 2H), 5.30 (s, CH2, 2H), 7.30–7.45 (m, CH, 5H), 8.54 (brs, NH, 1H);

13

C

NMR (101 MHz, CDCl3, δ): 10.7 (CH3), 11.5 (CH3), 15.5 (CH3), 17.3 (CH2), 65.5 (CH2), 124.2,
128.1 (CH), 128.2 (CH), 128.7 (CH ), 129.5, 136.8.

Benzyl 4-(3-bromopropyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate (2.4a):
Compound 2.2a (1.5 g, 4.7 mmol, 1 equiv) was cooled to 0 °C, and to it was added BH3THF (1 M, 24 mL, 24 mmol, 5 equiv) dropwise while stirring. The reaction mixture was allowed
to warm to ambient temperature and stirred for 5 h. Excess BH3-THF was quenched with
CH3OH (20 mL), and the solvent was removed under reduced pressure. The resulting residue
was dissolved in CH2Cl2 and washed with HCl (0.5 M, 2 × 20 mL). The organic layer was dried
with anhydrous K2CO3, and the solvent was removed under reduced pressure to yield 1.34 g
(98%) of reduced 2.2a as a white powder. 1H NMR (400 MHz, CDCl3, δ): 1.49 (brs, OH, 1H),
1.64–1.86 (m, CH2, 2H), 2.20 (s, CH3, 3H), 2.30 (s, CH3, 3H), 2.47 (t, J = 7.4 Hz, CH2, 2H), 3.64
(t, J = 5.6 Hz, CH2, 2H), 5.30 (s, CH2, 2H), 7.29–7.56 (m, CH, 5H), 8.79 (brs, NH, 1H);

13

C

NMR (101 MHz, CDCl3, δ): 10.8 (CH3), 11.6 (CH3), 20.3 (CH2), 33.6 (CH2), 62.5 (CH2), 65.6
(CH2), 116.6, 121.5, 127.8, 128.1 (CH), 128.2 (CH), 128.6 (CH), 130.2, 136.7, 161.5; HRESIMS
(m/z): [M + H]+ calcd for C17H22NO3, 288.1600; found, 288.1641.
To a solution of reduced 2.2a (0.90 g, 3.2 mmol, 1 equiv) in anhydrous CH2Cl2 was
added CBr4 (1.6 g, 4.8 mmol, 1.5 equiv). The resulting mixture was cooled to 0 °C and stirred
for 10 min under Ar in the dark. To this mixture was added PPh3 (1.3 g, 4.8 mmol, 1.5 equiv),
and the mixture was stirred for 1.5 h at ambient temperature under Ar in the dark. Solvent was
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removed under reduced pressure, and the resulting viscous oil was purified by silica gel
chromatography (1:5 ethyl acetate/hexanes) to obtain 0.83 g (74%) of 2.4a as an off white
powder. 1H NMR (400 MHz, CDCl3, δ): 1.92–2.12 (m, CH2, 2H), 2.23 (s, CH3, 3H), 2.32 (s,
CH3, 3H), 2.55 (t, J = 8.0 Hz, CH2, 2H), 3.40 (t, J = 8.0 Hz, CH2, 2H), 5.32 (s, CH2, 2H), 7.31–
7.51 (m, CH, 5H), 8.99 (brs, NH, 1H); 13C NMR (101 MHz, CDCl3, δ): 10.9 (CH3), 11.6 (CH3),
22.4 (CH2), 33.5 (CH2), 33.6 (CH2), 65.6 (CH2), 116.7, 120.4, 127.7, 128.1 (CH), 128.6 (CH),
130.6, 136.7, 161.5; HRESIMS (m/z): [M + H]+ calcd for C17H21NO2Br, 350.0756; found,
350.0941; TLC: Rf = 0.44 (1:5 ethyl acetate/hexanes).

Benzyl 5-(acetoxymethyl)-4-(3-ethyl)-3-methyl-1H-pyrrole-2-carboxylate (2.3b):
To a stirring mixture of 2.3a (1.0 g, 3.9 mmol, 1 equiv) in glacial acetic acid (50 mL) was
added acetic anhydride (15 mL) dropwise under Ar at ambient temperature. The reaction mixture
was stirred for 15 min; Pb(OAc)4 (2.5 g, 5.6 mmol, 1.4 equiv) was added; and stirring was
continued for 195 min. The reaction mixture was poured onto ice, and the resulting precipitate
was collected and washed with water (10 × 100 mL). The precipitate was dried under reduced
pressure, dissolved in CHCl3 (4 mL), and precipitated using petroleum ether (150 mL) to yield
1.0 g (82%) of 2.3b as a white fluffy powder. 1H NMR (400 MHz, CDCl3, δ): 1.11(t, J = 7.6 Hz,
CH2, 3H), 2.07 (s, CH3, 3H), 2.32 (s, CH3, 3H), 2.49 (q, J = 7.6 Hz, CH2, 2H), 5.05 (s, CH2, 2H),
5.33 (s, CH2, 2H), 7.31–7.48 (m, CH, 5H), 9.26 (brs, NH, 1H); 13C NMR (101 MHz, CDCl3, δ):
10.5 (CH3), 16.0 (CH3), 17.2 (CH2), 21.0 (CH3), 57.0 (CH2), 65.8 (CH2), 119.0, 126.6, 127.0,
127.1, 128.2 (CH), 128.6 (CH), 136.5, 161.4, 171.6.
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Benzyl 5-(acetoxymethyl)-4-(3-bromopropyl)-3-methyl-1H-pyrrole-2-carboxylate (2.4b):
To a stirring mixture of 2.4a (0.44 g, 1.2 mmol, 1 equiv) in glacial acetic acid (17 mL)
was added acetic anhydride (5 mL) dropwise under Ar at ambient temperature. The reaction
mixture was stirred for 15 min; Pb(OAc)4 (1.1 g, 2.5 mmol, 2 equiv) was added; and stirring was
continued for 1 h. The reaction mixture was poured on to ice, and the resulting precipitate was
collected and washed with water (10 × 50 mL). The precipitate was dried under reduced
pressure, dissolved in CH2Cl2 (2 mL), and filtered. The filtrate was precipitated using petroleum
ether (100 mL) to yield 0.45 g (93%) of 2.4b as a white fluffy powder. 1H NMR (400 MHz,
CDCl3, δ): 1.98–2.06 (m, CH2, 2H), 2.06 (s, CH3, 3H), 2.30 (s, CH3, 3H), 2.62 (t, J = 7.4 Hz,
CH2, 2H), 3.39 (t, J = 6.4 Hz, CH2, 2H), 5.05 (s, CH2, 2H), 5.31 (s, CH2, 2H), 7.31–7.50 (m, CH,
5H), 9.23 (brs, NH, 1H);

13

C NMR (101 MHz, CDCl3, δ): 10.7 (CH3), 21.1 (CH3), 22.2 (CH2),

33.3 (CH2), 33.8 (CH2), 57.0 (CH2), 65.9 (CH2), 119.3, 123.3, 126.8, 127.8 (CH), 128.3 (CH),
128.7 (CH), 136.4, 161.2, 171.7; HRESIMS (m/z): [M + H]+ calcd for C19H23NO4Br, 408.0811
found, 408.0588.
Benzyl-5,5’-(3,4-diethyl-1H-pyrrole-2,5-diyl)bis(methylene)bis(4-(3-bromopropyl)-3methyl-1H-pyrrole-2-carboxylate) (2.4c):
Compound 2.4b (0.39 g, 0.96 mmol, 2 equiv) and 3,4-diethylpyrrole (65 µL, 0.48 mmol,
1 equiv) were suspended in CH3OH (27 mL) under Ar in the dark and heated at 60 °C for 1 h
until a clear solution was obtained. To this clear solution was added p-toluene sulfonic acid (7.9
mg, 0.041 mmol, 0.085 equiv) in CH3OH (1 mL). The resulting reaction mixture was stirred for
1.5 h at 60 °C, at which point the volume was reduced by sparging N 2 through the reaction
mixture (5–10 min) until a precipitate started to form. Once precipitation started, N2 sparging
was stopped, and reaction was stirred for 4 h at 60 °C. The reaction mixture was concentrated to
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10 mL under reduced pressure and cooled to –20 °C for 2 h to promote precipitation. The
precipitate was separated, washed with cold CH3OH (0 °C, 2 mL) and dried under reduced
pressure to yield 0.24 g (60%) of 2.4b as a pink powder. 1H NMR (400 MHz, CDCl3, δ): 1.19 (t,
J = 7.4 Hz, CH3, 6H), 1.84–2.03(m, CH2, 4H), 2.26 (s, CH3, 6H), 2.42–2.66 (m, CH2, 8H), 3.36
(t, J = 6.2 Hz, CH2, 4H), 3.62 (brs, CH2, 4H), 4.35 (brs, CH2, 4H), 6.96–7.10 (m, CH, 4H), 7.24–
7.39 (m, CH, 6H), 8.85 (brs, NH, 1H), 11.33 (brs, NH, 2H);

13

C NMR (101 MHz, CDCl3, δ):

11.3 (CH3), 17.0 (CH3), 17.8 (CH2), 21.9 (CH2), 22.1(CH2), 33.3 (CH2), 33.6 (CH2), 65.2 (CH2),
117.3, 118.8, 119.3, 122.0, 126.2 (CH), 126.6, 127.1 (CH), 127.9 (CH), 133.7, 136.5, 162.5;
HRESIMS (m/z): [M + H]+ calcd for C42H50N3O4Br2, 818.2168; found, 818.2140.

Dimethyl-3,3’-(2,2-(3,4-diethyl-1H-pyrrole-2,5-diyl)bis(methylene)bis(5-formyl-4-methyl1H-pyrrole-3,2-diyl))dipropanoate (2.2d):
A mixture of tripyrrane 2.2c (0.38 g, 0.51 mmol, 1 equiv) and Pd/C (10%, 0.070 g, 0.067
mmol) in anhydrous THF (12 mL) was degassed under reduced pressure and then saturated with
hydrogen (1 atm), and the resulting reaction mixture was stirred for 6 h at ambient temperature
under an atmosphere of hydrogen. The reaction mixture was filtered through celite, and the
solvents were removed under reduced pressure to obtain deprotected 2.2c as a pink powder. To
deprotected 2.2c (0.29 g, 0.51 mmol, 1 equiv) was added trifluoroacetic acid (0.90 mL, 13 mmol,
25 equiv) dropwise under Ar at ambient temperature while stirring. Upon complete addition of
trifluoroacetic acid, the resulting solution was stirred for 10 min. The reaction mixture was
cooled to 20 °C, and triethylorthoformate (0.96 mL, 5.7 mmol, 11 equiv) was added dropwise.
The resulting reaction mixture was stirred at 20 °C for 10 min before allowing the reaction
mixture to warm to ambient temperature. Water (3.0 mL) was added dropwise to the stirring
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mixture immediately after the temperature warmed above 20 °C, and stirring at ambient
temperature was continued for 15 min. A dark red precipitate was collected and washed with
water (5 × 5 mL). The precipitate was suspended in a mixture of water/ethanol/ammonium
hydroxide (1:2:1 v/v/v, 5.0 mL) and stirred at ambient temperature for 1 h. The resulting yellow
precipitate was filtered and washed with water (3 × 3 mL) followed by cold ethanol (0 °C, 2.0
mL). The precipitate was dissolved in a methanol/water mixture (5:1, 3.6 mL), heated to 60 °C
for 5 min, cooled to ambient temperature, and concentrated under reduced pressure. The
resulting suspension was cooled at 20 °C for 4 h then filtered, and the precipitate was washed
with water (4.0 mL). Solvents were removed under reduced pressure to yield 171 mg (63%) of
2.2d as a light brown solid. 1H NMR (400 MHz, CDCl3, δ): 1.11 (t, J = 7.4 Hz, CH3, 6H), 2.21
(s, CH3, 6H), 2.31 (t, J = 7.8 Hz, CH2, 4H), 2.45 (q, J = 7.4 Hz, CH2, 4H), 2.71 (t, J = 7.8 Hz,
CH2, 4H), 3.64 (s, CH3, 6H), 3.87 (s, CH2, 4H), 9.09 (s, CH, 2H), 9.30 (s, NH, 1H), 10.52 (s,
NH, 2H);

13

C NMR (101 MHz, CDCl3 δ): 8.9 (CH3), 16.7 (CH3), 17.8 (CH2), 19.3 (CH2), 22.8

(CH2), 34.5 (CH2), 51.7 (CH3), 120.7, 120.9, 121.8, 128.2, 133.0, 138.7, 173.6 (CH), 175.6;
HRESIMS (m/z): [M + H]+ calcd for C30H40N3O6, 538.2917; found, 538.2917.

5,5’-(3,4-Diethyl-1H-pyrrole-2,5-diyl)bis(methylene)bis(4-ethyl-3-methyl-1H-pyrrole-2carbaldehyde) (2.3d):
Compound 2.3d was synthesized according to the procedure in reference 94 with some
modifications to the protocol. The modifications included addition and stirring of triflouroacetic
acid at ambient temperature, addition and stirring of triethylorthoformate at 20 °C, and
purification by precipitation with methanol at 20 °C, instead of extraction to yield 73% of 2.3d
as a light brown solid. 1H NMR (400 MHz, CDCl3, δ): 0.80–1.29 (m, CH3, 12H), 2.20 (s, CH3,
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6H), 2.32–2.56 (m, CH2, 8H), 3.84 (s, CH2, 4H), 9.14 (s, CH, 2H), 9.39 (s, NH, 1H), 10.11 (s,
NH, 2H); 13C NMR (101 MHz, CDCl3, δ): 8.8 (CH3), 15.1 (CH3), 16.5 (CH3), 16.9 (CH2), 17.7
(CH2), 22.7 (CH2), 120.8, 121.5, 124.8, 128.2, 132.9, 138.0, 175.6 (CH); HRESIMS (m/z): [M +
H]+ calcd for C26H36N3O2, 422.2808; found, 422.2808.

5,5’-(3,4-Diethyl-1H-pyrrole-2,5-diyl)bis(methylene)bis(4-(3-bromopropyl)-3-methyl-1Hpyrrole-2-carbaldehyde) (2.4d):
A mixture of tripyrrane 2.4c (0.60 g, 0.73 mmol, 1 equiv) and Pd/C (10%, 0.10 g, 0.095
mmol) in anhydrous THF (18 mL) was degassed under reduced pressure and saturated with
hydrogen (1 atm), and the reaction mixture was stirred for 6 h at ambient temperature under an
atmosphere of hydrogen. The reaction mixture was filtered through celite, and solvent was
removed under reduced pressure to obtain deprotected 2.4c as a pink powder. To deprotected
2.4c (0.46 g, 0.73 mmol, 1 equiv) was added trifluoroacetic acid (0.67 mL, 8.9 mmol, 12 equiv)
dropwise under Ar at ambient temperature while stirring. Upon complete addition of
trifluoroacetic acid, the resulting solution was stirred for 10 min. The reaction mixture was
cooled at 20 °C, and triethylorthoformate (0.79 mL, 4.8 mmol, 6.5 equiv) was added dropwise
over 15 min. The resulting reaction mixture was stirred at 20 °C for 15 min; the cold bath was
removed; and water (22 mL) was added dropwise without stirring immediately after the
temperature warmed above 20 °C. The reaction mixture was left to stand for 30 min at ambient
temperature, and a dark red precipitate was collected and washed with water (5 × 10 mL). The
precipitate was suspended in ethanol (8.6 mL), and a mixture of ammonium hydroxide/water
(1:3 v/v, 8.5 mL) was added. The reaction mixture was stirred at ambient temperature for 20 min.
The resulting precipitate was separated and washed with water (5 × 20 mL) until washings were
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neutral as measured by pH paper. The resulting solid was dissolved in CH2Cl2 (5 mL) and
precipitated using CH3OH/water (8:1, 45 mL). The resulting suspension was cooled to 20 °C
for 24 h, filtered, and washed with water (5.0 mL). Solvents were removed under reduced
pressure to yield 371 mg (84%) of 2.4d as a light brown solid. 1H NMR (400 MHz, CDCl3, δ):
1.12 (t, J = 7.4 Hz, CH3, 6H), 1.82–1.96 (m, CH2, 4H), 2.20 (s, CH3, 6H), 2.46 (q, J = 7.4 Hz,
CH2, 4H), 2.54 (t, J = 7.2 Hz, CH2, 4H), 3.31 (t, J = 6.4 Hz, CH2, 4H), 3.87 (brs, CH2, 4H), 9.07
(s, CH, 2H), 9.26 (brs, NH, 1H), 10.74 (brs, NH, 2H);

13

C NMR (101 MHz, CDCl3, δ): 9.2

(CH3), 16.8 (CH3), 17.9 (CH2), 22.3 (CH2), 22.9 (CH2), 33.3 (CH2), 33.4 (CH2), 120.6, 121.2,
121.8, 128.2, 133.3, 139.0, 175.5 (CH); HRESIMS (m/z): [M + H]+ calcd for C28H38N3O2Br2,
606.1331; found, 606.1338.
Sodium

3,3’-(2,2’-(3,4-diethyl-1H-pyrrole-2,5-diyl)bis(methylene)bis(5-formyl-4-methyl-

1H-pyrrole-3,2-diyl))dipropane-1-sulfonate (2.5d):
To a solution of 2.4d (0.20 g, 0.33 mmol, 1 equiv) in p-dioxane (12 mL) was added an
aqueous solution of KI (0.14 g, 0.80 mmol, 2.5 equiv, 2.0 mL), and the resulting mixture was
stirred for 30 min at 80 °C under Ar. To the resulting mixture was added an aqueous solution of
Na2SO3 (0.24 g, 1.9 mmol, 6.0 equiv, 2.0 mL), and the mixture was stirred for 24 h under Ar at
80 °C. Solvents were removed under reduced pressure, and the resulting residue was purified by
reverse-phase chromatography using RP-tC18 SPE Sep-Pak (stepwise gradient of 1:0→7:3
water/CH3OH). Volatiles were removed under reduced pressure, and the resulting residue was
dissolved in water (2 mL) and freeze dried to yield 0.16 g (76%) of 2.5d as a brown fluffy
powder. 1H NMR (400 MHz, D2O, δ): 0.91 (t, J = 6.6 Hz, CH3, 6H), 1.61–1.74 (m, CH2, 4H),
2.14 (s, CH3, 6H), 2.21–2.44 (m, CH2, 8H), 2.70 (t, J = 7.4 Hz, CH2, 4H), 3.80 (s, CH2, 4H), 9.06
(s, CH, 2H);

13

C NMR (101 MHz, D2O with dimethylsulfoxide-d6 internal standard δ): 9.8
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(CH3), 17.4 (CH3), 18.6 (CH2), 23.3 (CH2), 24.3 (CH2), 26.4 (CH2), 52.1 (CH2), 122.7, 123.0,
123.9, 129.0, 137.6, 141.8, 178.7 (CH); HRESIMS (m/z): [M + H]+ calcd for C28H38N3O8S2,
608.2100; found, 608.2116.

3,3’-(1,2-Phenylenebis(oxy))dipropan-1-ol (2.2e):
Compound 2.2e was synthesized according to the procedure in reference 92 with some
modifications to the protocol. The modification included purification using silica gel
chromatography (stepwise gradient of 2:1→4:1, ethyl acetate/hexanes) to yield 80% of 2.2e as a
white crystalline solid. 1H NMR (400 MHz, CDCl3, δ): 2.01–2.09 (m, CH2, 4H), 3.41 (brs, OH,
2H), 3.82–3.87 (m, CH2, 4H), 4.16 (t, J = 5.8 Hz, CH2, 4H), 6.80–6.92 (m, CH, 4H); 13C NMR
(101 MHz, CDCl3, δ): 32.2 (CH2), 61.3 (CH2), 68.0 (CH2), 113.4 (CH), 121.7 (CH), 148.8;
HRESIMS (m/z): [M + H]+ calcd for C12H18O4Na, 249.1103; found, 249.0938; TLC: Rf = 0.23
(2:1 ethyl acetate/hexanes)

3,3’-(1,2-Phenylenebis(oxy))dipropane-1-sulfonic acid (2.3e):
Catechol (0.72 g, 6.5 mmol, 1 equiv) was dissolved in a mixture of NaOH (0.65 g, 16
mmol, 2.7 equiv) and ethanol (35 mL) under Ar, and the resulting mixture was heated at reflux
until a clear solution was obtained. This mixture was added to propane sultone (1.8 g, 15 mmol,
2.5 equiv) dropwise over 30 min under Ar. The reaction mixture was heated at reflux under Ar
for 48 h. The reaction mixture was centrifuged while hot; liquid was decanted; and the resulting
residue was washed with hot ethanol (60 °C, 3 × 25 mL). The residue was dissolved in water (10
mL) and sparged with gaseous HCl for 3 min. The acid-saturated solution was centrifuged, and
the liquid was decanted and concentrated under reduced pressure. The concentrated liquid (3
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mL) was precipitated using CH3OH (47 mL) and cooled to –20 °C. The solid residue was
isolated, dissolved in water (5 mL), and purified by re-precipitation using CH3OH/diethyl ether
(8:1 v/v, 45 mL) at –20 °C. The precipitate was separated and washed with diethyl ether (2 × 25
mL). Volatiles were removed under reduced pressure to obtain 0.82 g (37%) of 2.3e as an off
white solid. 1H NMR (400 MHz, D2O, δ): 2.15–2.30 (m, CH2, 4H), 3.05–3.17 (m, CH2, 4H),
4.12 (t, J = 6.4 Hz, CH2, 4H), 7.03 (s, CH, 4H); 13C NMR (101 MHz, D2O with internal standard
of dimethylsulfoxide-d6, δ): 25.8 (CH2), 49.4 (CH2), 69.2 (CH2), 116.1 (CH), 123.7 (CH), 149.3;
HRESIMS (m/z): [M –2H + Na]– calcd for C12H16O8S2Na, 375.0184; found, 375.0247.

Sodium 3-(2-methoxyphenoxy)propane-1-sulfonate (2.4e):
2-Methoxyphenol (0.6 mL, 4 mmol, 1 equiv) was added to a mixture of NaOH (0.24 g,
6.0 mmol, 1.5 equiv) and ethanol (15 mL) under Ar in the dark, and the resulting reaction
mixture was heated at reflux until a homogeneous solution was obtained. This mixture was
added to propane sultone (0.74 g, 6.0 mmol, 1.5 equiv) dropwise under Ar. The reaction mixture
was heated at reflux under Ar for 20 h in the dark. The reaction mixture was centrifuged while
hot; liquid was decanted; and the resulting residue was washed with hot ethanol (60 °C, 3 × 20
mL). The residue was dissolved in water (5 mL), precipitated using ethanol (40 mL), and cooled
to –20 °C. The solid residue was isolated, and the volatiles were removed under reduced
pressure to obtain 0.83 g (84%) of 2.4e as an off white solid. 1H NMR (400 MHz, D2O, δ):
2.14–2.27 (m, CH2, 2H), 3.04–3.15 (m, CH2, 2H), 3.84 (s, CH3, 3H), 4.14 (t, J = 6.4 Hz, CH2,
2H), 6.95–7.14 (m, CH, 4H);

13

C NMR (101 MHz, D2O with an internal standard of

dimethylsulfoxide-d6, δ): 25.6 (CH2), 49.2 (CH2), 56.9 (CH3), 68.6 (CH2), 113.6 (CH), 114.9
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(CH), 122.9 (CH), 123.2 (CH), 148.5, 149.8.; HRESIMS (m/z): [M – H]– calcd for C10H13O5S,
245.0484; found, 245.0491.

3,3’-(4,5-Dinitro-1,2-phenylene)bis(oxy)dipropane-1-sulfonic acid (2.3f):
Sulfonic acid 2.3e (0.24 g, 0.68 mmol, 1 equiv) was dissolved in glacial acetic acid (3.9
mL) and stirred for 15 min at 15 °C. To this mixture was added aqueous HNO3 (70%, 2.5 mL)
dropwise over a period of 15 min while maintaining the temperature of the reaction mixture at 15
°C. After the addition, the reaction mixture was warmed to ambient temperature and stirred for
15 min. The reaction mixture was cooled to 15 °C, and fuming HNO3 (6.6 mL) was added
dropwise over a period of 30 min while the temperature of the reaction mixture was held at 15
°C. After the addition, the reaction mixture was warmed to ambient temperature and stirred for
64 h. The reaction mixture was concentrated under reduced pressure, and cold methanol (0 °C,
2.0 mL) was added to form a precipitate. The precipitate was collected and dried under reduced
pressure. Purification was performed using an RP-tC18 SPE Sep-Pak column (stepwise gradient
of 1:9→1:4 CH3OH/water) to yield 151.6 mg (50%) of 2.3f as a yellow solid. 1H NMR (400
MHz, D2O, δ): 2.22–2.37 (m, CH2, 4H), 3.11 (t, J = 7.4 Hz, CH2, 4H), 4.32 (t, J = 6.4 Hz, CH2,
4H), 7.60 (s, CH, 2H); 13C NMR (101 MHz, D2O with internal standard of dimethylsulfoxide-d6,
δ): 25.5 (CH2), 49.1 (CH2), 70.2 (CH2), 110.5 (CH), 137.6, 152.7; HRESIMS (m/z): [M – H]–
calcd for C12H15N2O12S2, 443.0066; found, 443.0062.

3-(2-Methoxy-4,5-dinitrophenoxy)propane-1-sulfonic acid (2.4f):
Sulfonic acid 2.4e (0.80 g, 3.3 mmol, 1 equiv) was dissolved in glacial acetic acid (19
mL) and stirred for 10 min at 15 °C. To this mixture was added aqueous HNO3 (70%, 12 mL)
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dropwise over a period of 15 min while maintaining the temperature of the reaction mixture at 15
°C. After the addition, the reaction mixture was warmed to ambient temperature and stirred for
15 min. The reaction mixture was cooled to 15 °C, and fuming HNO3 (30 mL) was added
dropwise over a period of 30 min while the temperature of the reaction mixture was held at 15
°C. After the addition, the reaction mixture was warmed to ambient temperature and stirred for
46 h. The reaction mixture was concentrated under reduced pressure, and the resulting residue
was dissolved in water (0.5 mL), and precipitated using CH3OH/diethyl ether (1:1, 50 mL). The
precipitate was collected and dried under reduced pressure to yield 0.80 g (72%) of 2.4f as a
yellow solid. 1H NMR (400 MHz, D2O, δ): 2.22–2.33 (m, CH2, 2H), 3.09 (t, J = 7.6 Hz, CH2,
2H), 3.96 (s, CH3, 3H), 4.24–4.32 (m, CH2, 2H), 7.51–7.56 (m, CH, 2H); 13C NMR (101 MHz,
D2O with internal standard of dimethylsulfoxide-d6, δ): 25.3 (CH2), 48.8 (CH2), 58.3 (CH3), 69.9
(CH2), 109.0 (CH), 109.7 (CH), 137.3, 152.2, 153.1; HRESIMS (m/z): [M – H]– calcd for
C10H11N2O9S, 335.0185; found, 335.0189.

3,3’-(4,5-Diamino-1,2-phenylene)bis(oxy)dipropanoic acid hydrochloride salt (2.2g):
A mixture of dinitro compound 2.2f (0.40 g, 1.2 mmol, 1 equiv), Pd/C (10%, 0.11 g, 0.10
mmol), and ethanol (18 mL) was sonicated until 2.2f was dissolved. The resulting reaction
mixture was degassed under reduced pressure, saturated with hydrogen (1 atm), and heated at
reflux for 3 h under an atmosphere of hydrogen. Solvent was removed under reduced pressure;
HCl (1 M, 10 mL) was added; and the resulting mixture was filtered through a 0.2 μm syringe
filter. The filtrate was concentrated by removing solvent under reduced pressure to yield 367.3
mg (88%) of 2.2g as a purple hygroscopic solid. 1H NMR (400 MHz, D2O, δ): 2.70 (t, J = 6.0
Hz, CH2, 4H), 4.15 (t, J = 5.6 Hz, CH2, 4H), 6.96 (s, CH, 2H); 13C NMR (101 MHz, D2O with
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internal standard of dimethylsulfoxide-d6, δ): 35.4 (CH2), 67.3 (CH2), 111.9 (CH), 120.8, 149.1,
176.8; HRESIMS (m/z): [M − H]– calcd for C12H15N2O6, 283.0930; found, 283.0936.

4,5-Diethyl-10,23-dimethyl-9,24-bis(methylpropanoate)-16,17-bis((methylpropanoate)oxy)13,20,25,26,27-pentaazapentacyclo-[20.2.1.13,6.18,11,.014,19]heptacosa3,5,8,10,12,14,16,18,20,22,24-undecaene (2.2L):
To a mixture of tripyrrole 2.2d (0.12 g, 0.22 mmol, 1 equiv) in toluene/CH3OH (6:1, 140
mL) under Ar was added a solution of diamine salt 2.2g (0.080 g, 0.22 mmol, 1 equiv) in
CH3OH (4.0 mL). To the resulting reaction mixture was added HCl (11.6 M, 0.05 mL, 0.6 mmol,
3 equiv), and the mixture was heated at 80 °C for 6 h under Ar. The reaction mixture was cooled
to ambient temperature; K2CO3 (83 mg, 0.60 mmol, 3 equiv) was added; and stirring was
continued for 30 min. The reaction mixture was filtered, and the filtrate was concentrated under
reduced pressure. Solids were dissolved in methanol (4.0 mL) and cooled at 20 °C for 16 h to
promote precipitation. The precipitate was collected, washed with diethyl ether (2.0 mL), and
solvents were removed under reduced pressure to yield 76.4 mg (58%) of 2.2L as a bright red
solid. 1H NMR (500 MHz, CDCl3, δ): 1.06 (t, J = 7.5 Hz, CH3, 6H), 2.27 (s, CH3, 6H), 2.38 (q, J
= 7.5 Hz, CH2, 4H), 2.46 (t, J = 7.8 Hz, CH2, 4H), 2.70–2.91 (m, CH2, 8H), 3.71 (s, CH3, 6H),
3.73 (s, CH3, 6H) 3.96 (dd, J = 15.5, 123.4 Hz, CH2, 4H), 4.25 (brs, CH2, 4H), 7.16 (s, CH, 2H),
8.30 (s, CH, 2H), 11.07 (s, NH, 1H), 12.25 (s, NH, 2H);

13

C NMR (126 MHz, CDCl3, δ): 9.8

(CH3), 16.7 (CH3), 17.8 (CH2), 19.5 (CH2), 22.2 (CH2), 34.4 (CH2), 35.2 (CH2), 51.81 (CH3),
51.82 (CH3), 65.2 (CH2), 102.6 (CH), 120.3, 120.4, 121.2, 125.3, 131.0, 133.5, 140.2, 141.6
(CH), 148.0, 171.5, 173.2; HRESIMS (m/z): [M + H]+ calcd for C44H56N5O10, 814.4027; found,
814.4015; UVvis (30% CH3OH in water) max, nm (ε): 364 (48400).
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4,5-Diethyl-10,23-dimethyl-9,24-bis(ethyl)-16,17-bis((propanesulfonicacid)oxy)13,20,25,26,27-pentaazapentacyclo-[20.2.1.13,6.18,11,.014,19]heptacosa3,5,8,10,12,14,16,18,20,22,24-undecaene (2.4L):
To a mixture of dinitrosulfonic acid 2.3f (52.8 mg, 0.118 mmol, 1 equiv) in
water/CH3OH (1:2, 3.6 mL) was added Pd/C (10%, 26.8 mg, 0.0252 mmol). The resulting
reaction mixture was degassed under reduced pressure and saturated with hydrogen (1 atm). The
reaction mixture was heated at reflux for 40 min under an atmosphere of hydrogen until the
solution became colorless. The resulting suspension was filtered through a 0.2 μm syringe filter
into a mixture of 2.3d (50.4 mg, 0.118 mmol, 1 equiv) in CH3OH/toluene/water (25:5:1, 62 mL)
and HCl (11.6 M, 0.030 mL, 0.35 mmol, 3 equiv). The reaction mixture was stirred under Ar for
6.5 h. Solvents were removed under reduced pressure, and the resulting residue was precipitated
with CH3OH (5 mL) at –20 °C. The precipitate was isolated and purified by reverse-phase
chromatography using an RP-tC18 SPE Sep-Pak (stepwise gradient of 1:1→1:4 water/CH3OH).
Volatiles were removed under reduced pressure to yield 37 mg (41%) of 2.4L as a red powder.
1

H NMR (600 MHz, dimethylsulfoxide-d6, δ): 1.01 (t, J = 7.5 Hz, CH3, 6H), 1.11 (t, J = 7.5 Hz,

CH3, 6H), 2.01–2.07 (m, CH2, 4H), 2.30–2.37 (m, CH2, CH3, 10H), 2.50–2.53 (m, CH2, 4H),
2.58 (t, J = 6.9 Hz, CH2, 4H), 3.95 (s, CH2, 4H), 4.26 (t, J = 6.9 Hz, CH2, 4H), 7.57 (s, CH, 2H),
8.72 (s, CH, 2H), 10.43 (s, NH, 1H), 11.17 (s, NH, 2H); 13C NMR (151 MHz, dimethylsulfoxided6, δ); 8.5 (CH3), 14.4 (CH3), 15.1 (CH3), 15.9 (CH2), 16.1 (CH2), 22.0 (CH2), 23.6 (CH2), 46.7
(CH2), 66.6 (CH2), 101.3 (CH), 119.4, 120.0, 123.5, 125.1, 140.5 (CH), 147.1; HRESIMS (m/z) :
[M – H]– calcd for C38H50N5O8S2, 768.3101; found, 768.3099; UVvis (30% CH3OH in water)
max, nm (ε): 368 (38417).
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Diethyl-10,23-dimethyl-9,24-bis(propanesulfonicacid)-16-((propanesulfonicacid)oxy)-17methoxy-13,20,25,26,27-pentaazapentacyclo-[20.2.1.13,6.18,11,.014,19]heptacosa3,5,8,10,12,14,16,18,20,22,24-undecaene (2.5L):
To a mixture of dinitrosulfonic acid 2.4f (17 mg, 0.050 mmol, 1 equiv) in water/CH3OH
(1:2, 1.8 mL) was added Pd/C (10%, 11 mg, 0.0010 mmol). The resulting reaction mixture was
degassed under reduced pressure and saturated with hydrogen (1 atm). The reaction mixture was
heated at reflux for 75 min under an atmosphere of hydrogen until the solution became colorless.
The resulting suspension was filtered through a 0.2 μm syringe filter into a mixture of 2.5d in
CH3OH/water (15:1, 32 mL) and HCl (11.6 M, 0.020 mL, 0.23 mmol, 4.6 equiv). The reaction
mixture was stirred under Ar for 6 h. Solvents were removed under reduced pressure, and the
resulting residue was purified by reverse-phase chromatography using an RP-tC18 SPE Sep-Pak
(stepwise gradient of 1:0→7:3 water/CH3OH). Volatiles were removed under reduced pressure,
and the resulting residue was dissolved in water (2 mL) and freeze dried to yield 24 mg (57%) of
2.5L as a red fluffy powder. 1H NMR (600 MHz, CD3OD/D2O (5:2), δ): 0.87 (brs, CH3, 6H),
1.90 (brs, CH2, 4H), 2.09 (brs, CH2, 2H), 2.20–2.36 (m, CH2, CH3, 10H), 2.65 (brs, CH2, 4H),
2.81 (brs, CH2, 6H), 3.88 (s, CH3, 3H), 4.02 (brs, CH2, 4H), 4.18 (brs, CH2, 2H), 7.27–7.40 (m,
CH, 2H), 8.43 (s, CH, 2H); 13C NMR (151 MHz, CD3OD/D2O (5:2), δ): 10.0 (CH3), 16.8 (CH3),
18.2 (CH2), 23.3 (CH2), 24.2 (CH2), 25.1 (CH2), 26.2 (CH2), 49.8 (CH2), 51.7 (CH2), 57.4 (CH3),
68.9 (CH2), 103.8 (CH), 104.6 (CH), 121.9, 123.5, 123.7, 124.5, 124.6, 126.1, 126.5, 127.0,
127.2, 142.6 (CH), 142.9 (CH), 143.6, 149.3, 150.7, 152.5; HRESIMS (m/z): [M – H]– calcd for
C38H50N5O11S3, 848.2669; found, 848.2674; UVvis (30% CH3OH in water) max, nm (ε): 365
(49529), 459 (sh, 15588).
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4,5-Diethyl-10,23-dimethyl-9,24-bis(propanesulfonicacid)-16,17bis((propanesulfonicacid)oxy)-13,20,25,26,27-pentaazapentacyclo[20.2.1.13,6.18,11,.014,19]heptacosa-3,5,8,10,12,14,16,18,20,22,24-undecaene (2.6L):
To a mixture of dinitrosulfonic acid 2.3f (23 mg, 0.050 mmol, 1 equiv) in water/CH3OH
(1:2, 1.8 mL) was added Pd/C (10%, 11 mg, 0.0010 mmol). The resulting reaction mixture was
degassed under reduced pressure and saturated with hydrogen (1 atm). The reaction mixture was
heated at reflux for 35 min under an atmosphere of hydrogen until the solution became colorless.
The resulting suspension was filtered through a 0.2 μm syringe filter into a mixture of 2.5d in
CH3OH/water (15:1, 32 mL) and HCl (11.6 M, 0.020 mL, 0.23 mmol, 4.6 equiv). The reaction
mixture was stirred under Ar for 6 h. Solvents were removed under reduced pressure, and the
resulting residue was purified by reverse-phase chromatography using an RP-tC18 SPE Sep-Pak
(stepwise gradient of 1:0→4:1 water/CH3OH). Volatiles were removed under reduced pressure,
and the resulting residue was dissolved in water (2 mL) and freeze dried to yield 25 mg (53%)
of 2.6L as a red fluffy powder. 1H NMR (600 MHz, CD3OD/D2O (5:2), δ): 0.86 (t, J = 7.5 Hz,
CH3, 6H), 1.86–1.94 (m, CH2, 4H), 2.05–2.11 (m, CH2, 4H), 2.34 (brs, CH2, CH3, 10H), 2.61–
2,68 (m, CH2, 4H), 2.78–2.84 (m, CH2, 8H), 4.04(s, CH2, 4H), 4.15–4.20 (m, CH2, 4H), 7.35 (s,
CH, 2H), 8.45 (s, CH, 2H); 13C NMR (151 MHz, CD3OD/D2O (5:2), δ): 10.2 (CH3), 16.9 (CH3),
18.2 (CH2), 23.3 (CH2), 24.4 (CH2), 25.1 (CH2), 26.3 (CH2), 49.8 (CH2), 51.8 (CH2), 69.0 (CH2),
105.6 (CH), 121.7, 123.8, 124.4, 125.3, 127.7, 142.9 (CH), 144.7, 149.8, 153.9; HRESIMS
(m/z): [M – H]– calcd for C40H54N5O14S4, 956.2550; found, 956.2527; UVvis (30% CH3OH in
water) max, nm (ε): 363 (57217), 467 (sh, 16283).
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GdIII texaphyrin complex 2.2:
To a stirring solution of texaphyrin 2.2L (0.060 g, 0.074 mmol, 1 equiv) in a mixture of
CH2Cl2/CH3OH (1:4, 5 mL) was added triethylamine (99 µL, 0.74 mmol, 10 equiv). To the
resulting solution was added Gd(OAc)3·4H2O (60 mg, 0.15 mmol, 2 equiv), and the reaction
mixture was heated at 60 °C while sparging with air until the peak intensity ratio (742 nm/364
nm) become constant (4.5 h). Solvents were removed under reduced pressure, and the resulting
residue was purified using silica gel chromatography (stepwise gradient of 1:9→1:4
CH3OH/CH2Cl2). Precipitation from CH3OH/CH2Cl2 (1:2, 0.5 mL) layered with CH3OH/diethyl
ether (1:1, 3 mL) yielded 36.4 mg (45%) of 2.2 as a green solid. HRESIMS (m/z): [M + AcO]+
calcd

for

C46H53N5O12Gd,

1022.2917;

found,

1022.2921;

Anal.

Calcd

for

C44H50N5O10GdCl3·CH3COOH·3H2O: C, 46.60; H, 5.02; N, 5.91. Found: C, 46.78; H, 4.64; N,
6.10; UVvis (30% CH3OH in water) max, nm (ε): 742 (32291), 470 (90902), 416 (sh, 52916);
TLC: Rf = 0.24 (1:9 CH3OH/CH2Cl2).

GdIII texaphyrin complex 2.3:
To a mixture of tripyrrole 2.3d (72 mg, 0.16 mmol, 1 equiv) in THF/toluene (5:1 v/v, 90
mL) and HCl (11.6 M, 0.1 mL, 0.8 mmol, 5 equiv) was added a solution of diamine salt 2.2g
(0.060 g, 0.16 mmol, 1 equiv) in water (1.0 mL), and the mixture was heated at 80 °C for 8.5 h
under Ar. Solvents were removed under reduced pressure. To the resulting residue (0.10 g, 0.15
mmol, 1 equiv) in CH3OH (8 mL) was added triethylamine (0.21 mL, 1.5 mmol, 10 equiv). To
the resulting solution was added Gd(OAc3)3·4H2O (0.30 g, 0.75 mmol, 5 equiv), and the reaction
mixture was heated at 60 °C while sparging with air until the peak intensity ratio (740 nm/370
nm) became constant (20 h). Solvents were removed under reduced pressure. The resulting
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residue was washed with CH3OH, dissolved in CH2Cl2, and purified by acidic alumina
chromatography (stepwise gradient of 1:1:0→0:1:0.01 CH2Cl2/CH3OH/AcOH). Volatiles were
removed under reduced pressure to yield 27 mg (22%) of 2.3 as a green powder. HRESIMS
(m/z): [M – H]+ calcd for C38H41N5O6Gd, 821.2303; found, 821.3124 ; UVvis (30% CH3OH in
water) max, nm (ε): 740 (30004), 474 (80403), 416 (sh, 48902).

GdIII texaphyrin complex 2.4:
To a stirring solution of texaphyrin 2.4L (22 mg, 0.028 mmol, 1 equiv) in a mixture of
CH2Cl2/CH3OH (1:2.5 v/v, 2.8 mL) was added triethylamine (40 µL, 0.28 mmol, 10 equiv). To
the resulting solution was added Gd(OAc3)3·4H2O (46 mg, 0.11 mmol, 4 equiv), and the reaction
mixture was heated at 60 °C while sparging with air until the peak intensity ratio (738 nm/368
nm) became constant (4 h). Solvents were removed under reduced pressure, and purified using
silica gel chromatography (stepwise gradient of 1:9→1:4 CH3OH/CH2Cl2). Purification by
precipitation from CH3OH (5 mL) layered with diethyl ether (25 mL) yielded 9.7 mg (37%) of
2.4 as a green solid. HRESIMS (m/z): [M + Na]+ calcd for C38H44N5O8S2GdNa, 940.1755; found,
940.1725; Anal. Calcd for C38H45N5O8GdS2Na2·3H2O: C, 44.69; H, 5.03; N, 6.86. Found: C,
44.86; H, 5.03; N, 6.49; UVvis (30% CH3OH in water) max, nm (ε): 738 (27878), 473 (88060),
416 (sh, 44727); TLC: Rf = 0.26 (1:4 CH3OH/CH2Cl2).

GdIII texaphyrin complex 2.5:
To a stirring solution of texaphyrin 2.5L (50 mg, 0.059 mmol, 1 equiv) in CH3OH (6 mL)
was added triethylamine (0.080 mL, 0.59 mmol, 10 equiv). To the resulting solution was added
Gd(OAc3)3·4H2O (120 mg, 0.29 mmol, 5 equiv), and the reaction mixture was heated at 60 °C
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while sparging with air until the peak intensity ratio (742 nm/365 nm) became constant (22 h).
Solvents were removed under reduced pressure, and the resulting residue was purified by
reverse-phase chromatography using an RP-tC18 SPE Sep-Pak (stepwise gradient of 1:0→7:3
water/CH3OH). Volatiles were removed under reduced pressure. The resulting residue was
dissolved in water (2 mL) and freeze dried to yield 30.2 mg (51%) of 2.5 as a green fluffy
powder. HRESIMS (m/z): [M – H]+ calcd for C38H45N5O11S3Gd, 1001.1524; found, 1001.2540;
Anal. Calcd for C38H43N5O11GdS3Na5·5H2O: C, 37.90; H, 4.44; N, 5.82. Found: C, 37.77; H,
3.87; N, 5.82; UVvis (30% CH3OH in water) max, nm (ε): 742 (34571), 470 (93523), 416 (sh,
46904). HPLC chromatogram on page 116 of Appendix B.

GdIII texaphyrin complex 2.6:
To a stirring solution of texaphyrin 2.6L (0.048 g, 0.049 mmol, 1 equiv) in CH3OH (8
mL) was added triethylamine (0.070 mL, 0.49 mmol, 10 equiv). To the resulting solution was
added Gd(OAc3)3·4H2O (0.10 g, 0.25 mmol, 5 equiv), and the reaction mixture was heated at 60
°C while sparging with air until the peak intensity ratio (743 nm/363 nm) became constant (6 h).
Solvents were removed under reduced pressure, and the resulting residue was purified by
reverse-phase chromatography using an RP-tC18 SPE Sep-Pak (stepwise gradient of 1:0→7:3
water/CH3OH). Volatiles were removed under reduced pressure. The resulting residue was
dissolved in water (2 mL) and freeze dried to yield 30.7 mg (55%) of 2.6 as a green fluffy
powder. HRESIMS (m/z): [M – H]+ calcd for C40H49N5O14S4Gd, 1109.1411; found, 1109.2557;
Anal. Calcd for C40H46N5O14GdS4Na8·8H2O: C, 33.50; H, 4.36; N, 4.88. Found: C, 33.55; H,
3.84; N, 4.85; UVvis (30% CH3OH) max, nm (ε): 743 (30486), 472(82734), 416 (sh, 43146).
HPLC chromatogram on page 117 of Appendix B.
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CHAPTER 3. A multimodal, β-amyloid-targeted contrast agent
Portions of this chapter are reproduced by permission of The Royal Society of Chemistry from
Vithanarachchi, S. M.; Allen, M. J. Chem. Commun. 2013, 49, 4148–4150.
http://pubs.rsc.org/en/content/articlepdf/2013/cc/c2cc36583a
Introduction
β-Amyloid plaques are a diagnostic marker of Alzheimer’s disease, which is one of the
most common neurodegenerative diseases in the world;99 hence, detection of β-amyloid plaques
is important in the diagnosis of, in the monitoring of treatments for, and in research related to
Alzheimer’s disease. The β-amyloid aggregates that comprise plaques are often detected using
fluorescent dyes or β-amyloid-targeted radiolabels that interact with β-amyloid aggregates.100–105
However, fluorescence microscopy has limited tissue penetration, and radiolabels for nuclear
imaging use harmful ionizing radiation. Magnetic resonance imaging (MRI) is a non-invasive
imaging technique with excellent tissue penetration and high spatial resolution (25–100 mm)6
that has the potential to overcome the limitations of fluorescence microscopy and nuclear
imaging with respect to the detection of β-amyloid aggregates. MRI has been used in several
imaging studies of β-amyloid plaques.35,36,106–110 In these studies, both transverse relaxation time
(T2)-weighted and longitudinal relaxation time (T1)-weighted imaging methods were
reported.35,36,106–109 The T1-weighted methods are more desirable because T1-weighted imaging
can distinguish plaques from hemorrhages and blood vessels unlike T2-weighted methods.
Although T1-weighted imaging is desirable, it suffers from poor contrast enhancement of plaques
leading to a widespread interest in the labeling of plaques with target-specific contrast agents.
Examples of β-amyloid-targeting groups that have been reported include β-amyloid
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peptides,35,36,107 monoclonal antibodies,108 and β-amyloid-binding dyes.109 Agents composed of
conjugates of these targeting groups are capable of labeling β-amyloid plaques, but possible
amyloidogenesis, toxicity, and the large size of these contrast agents limit their usefulness. These
limitations reveal the need for new β-amyloid-targeted contrast agents with higher efficiency,
smaller size, and non-amyloidogenic and non-toxic properties to make MRI a useful technique in
β-amyloid imaging.
This chapter describes a β-amyloid-targeted contrast agent for MRI that is more efficient
than current clinical contrast agents. To target β-amyloid aggregates, a non-toxic small molecule
that can be traced with fluorescence microscopy was used; thus, this agent is multi-modal being
detectable by both MRI and fluorescence microscopy. The multimodal contrast agent was
synthesized using the conjugation strategy for target specific molecules by linking a clinically
approved contrast agent to a target-specific moiety.111 For the target-specific moiety, curcumin,
1,7-bis-(4-hydroxy-3-methoxy-phenyl)-1,6-heptadiene-3,5-dione, was chosen because it is nontoxic, interacts with β-amyloid aggregates, is non amyloidogenic, and inhibits aggregate
formation.37,100–103 Moreover, curcumin is fluorescent and has been used for imaging β-amyloid
plaques with fluorescence microscopy.37,100,101 Curcumin conjugates are often synthesized via the
total synthesis of curcumin derivatives103,112,113 or the direct reaction of linkers with
commercially available curcumin.113,114 Total synthetic routes are tedious and limited to the
synthesis of specific derivatives. Alternatively, the direct reaction of commercially available
curcumin provides shorter synthetic routes and has been used to synthesize conjugates with
reactive functional groups including alkenes, alcohols, esters, amides, cyanide, carboxylic acids,
and azides.113,114 To facilitate conjugation to curcumin, an amine-functionalized linker was
introduced at one of the phenolic sites of curcumin. That amine-functionalized curcumin is
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expected to be a useful intermediate for other conjugations of curcumin because of the facile
synthesis and resistance of amine-derived conjugates including amides, thioureas, ureas, and
carbamates, to hydrolysis in enzyme-rich biological environments.115 The phenolic group was
selected as a site of conjugation because conjugations to this position do not inhibit the targeting
ability of curcumin.103 Furthermore, the amine group enabled facile reaction with an
isothiocyanate derivative of GdIIIdiethylenetriaminepentaacetate (GdIIIDTPA), which is a
clinically approved contrast agent.
In vitro studies of interaction between multimodal contrast agent and β-amyloid aggregates
Conjugate 2.1 was synthesized via the direct reaction of commercially available curcumin
with linker 2.1c to obtain amine linker containing curcumin 2.1d as described in Chapter 2
(Scheme 2.1). The reactions were performed in the dark because of the photoinstability of
curcumin.117 The amine group was deprotected with HCl and reacted with isothiocyanatecontaining GdIIIDTPA, 2.1f, to obtain curcumin-conjugated contrast agent 2.1. After synthesis,
the efficiency of conjugate 2.1 as a contrast agent for MRI was determined as described under
experimental procedures. The longitudinal relaxivity (r1) of 2.1 is 13.63 ± 0.03 mM–1 s–1
[phosphate buffered saline (PBS), pH 7.4, 1.4 T, and 37 °C]. This value is 4.1 times greater than
that of clinically approved GdIIIDTPA under the same conditions (3.30 ± 0.06 mM–1 s–1 ). The
high relaxivity of 2.1 demonstrates that it is an efficient contrast agent. The efficiency is likely
caused by a slowing of the molecular reorientation rate upon conjugation to curcumin and
potential aggregation in solution.20 To measure the interaction of 2.1 with β-amyloid aggregates,
the T1 of solutions containing complex 2.1 was measured in the presence and absence of βamyloid fibrils that were prepared as described in experimental procedures. The formation of
fibrils (diameters of 200–600 nm) was confirmed with dynamic light scattering and transmission
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electron microscopy. Different stoichiometries (0, 0.5, 1, and 2 equiv relative to 2.1) of
aggregated β-amyloid were incubated with complex 2.1, and T1 values were measured at a
clinically relevant field strength (1.4 T) at 37 °C in PBS (pH = 7.4). As a non-binding control, T1
measurements of β-amyloid aggregates at each concentration were measured in the presence of
clinically approved GdIIIDTPA, and all measurements were replicated with independently
prepared samples. The T1 of samples containing conjugate 2.1 that were incubated with 1 or 2
equiv of β-amyloid aggregates were shorter than the blank of 2.1 that did not contain β-amyloid
aggregates (Student t test, 99% confidence interval). However, the GdIIIDTPA control did not
have different T1 values at any concentration of β-amyloid aggregates (Student t test, 99%
confidence interval) with respect to GdIIIDTPA in the absence of β-amyloid aggregates. To
quantify the magnitude of the influence of the interaction of fibrils with 2.1 on relaxation rates,
values of ∆1/T1 were calculated for samples containing conjugate 2.1, the GdIIIDTPA control,
and PBS [eq (3.1)]. In eq (3.1), ∆1/T1 is the change in 1/T1 due to the interaction with β-amyloid
aggregates; (1/T1)n is the relaxation rate in the presence of n equiv of β-amyloid aggregates
where n = 0, 0.5, 1, or 2; and (1/T1)0 is the relaxation rate in the absence of β-amyloid aggregates.
(3.1)
A plot of ∆1/T1 vs equiv of β-amyloid aggregates demonstrates that there is an increase in
relaxation rate for 2.1 with increasing amounts of β-amyloid aggregates (Figure 3.1).
A 67 × 10–3 s–1 (9%) change in 1/T1 in the presence of 2 equiv of β-amyloid aggregates was
observed compared to in the absence of aggregates. The controls of GdIIIDTPA with β-amyloid
aggregates and the β-amyloid aggregates alone did not show an increase in relaxation rate as a
function of β-amyloid concentration. Values of T1 were expected to decrease upon the interaction
of contrast agents to macromolecules, like fibrillar aggregates, due to the reduction in tumbling
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rate based on Solomon–Bloembergen–Morgan theory.20,32,117 Hence, a decrease in T1 values in
the presence of β-amyloid aggregates provides evidence of the interaction of conjugate 2.1 with
β-amyloid aggregates.

∆1/T1 (×10–3 s–1)
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0
0

β-amyloid aggregates (equiv)

2

Figure 3.1. Plot showing the change in relaxation rate (∆1/T1) as a function of
the amount of β-amyloid (βA) aggregates in PBS. The relaxation rate of 2.1
increases in the presence of βA, and the rate of the control samples do not: 2.1
+ βA (□); GdIIIDTPA + βA (○); and βA (◊). Error bars represent standard error
of the mean.
To explore the multimodal nature of complex 2.1, the effect of β-amyloid aggregates on
the fluorescence emission of conjugate 2.1 was investigated. Emission spectra were acquired at
the end of each T1 measurement (Figure 3.2), and the fluorescence emission maximum of
conjugate 2.1 (516 nm) was blue shifted 9 nm in the presence of 2 equiv of β-amyloid
aggregates. Furthermore, the fluorescence intensity of conjugate 2.1 increased by 43% in the
presence of 2 equiv of β-amyloid aggregates relative to 2.1 in the absence of β-amyloid
aggregates. Similar observations have been reported for β-amyloid-specific fluorescent dyes due
to their interaction with β-amyloid aggregates,37,104,109,118 thus agreeing with the measurements in
this thesis and providing further indication of the presence of an interaction of complex 2.1 with
the β-amyloid aggregates. The changes in emission wavelength and intensity make conjugate 2.1
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a multimodal imaging agent for β-amyloid plaques. Importantly, these probes allow for
validation of results using orthogonal modalities: The multimodal nature of conjugate 2.1
enables the validation of MRI results with fluorescence studies.

Figure 3.2. Emission spectra (λex = 385 nm) of 2.1 and GdIIIDTPA incubated
with β-amyloid aggregates (βA) in PBS: 2 equiv βA + 2.1 (∙∙ III); 1 equiv. βA +
2.1 (
); 0.5 equiv βA + 2.1 (∙ ); 2.1 (---), 2 equiv βA + Gd DTPA (∙∙∙); and
βA (─).The maximum emission of 2.1 undergoes a 9 nm blue shift and 43%
increase in intensity upon interaction with 2 equiv of βA.

Experimental procedures
Commercially available chemicals were of reagent-grade purity or better and were used
without purification unless otherwise noted. β-Amyloid peptide (1–42) was obtained from
American Peptide Company Inc. GdIIIdiethylenetriaminepentaacetate (GdIIIDTPA) was obtained
as a 0.5 M aqueous solution from Bayer HealthCare Pharmaceutical Inc. Water was purified
using a PURELAB Ultra Mk2 water purification system (ELGA). Phosphate buffered saline
(PBS) (1×, 11.9 mM phosphate, 137 mM NaCl, and 2.7 mM KCl, pH = 7.4) was used for
amyloid fibril formation and relaxation time measurements.
Dynamic light scattering measurements were obtained on a Zetasizer nanoparticle
analyzer equipped with 633 nm helium–neon laser (NanoZS, Malvern Instruments Ltd.).
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Transmission electron microscopy (TEM) was performed on a JEOL-2010 FasTEM
Transmission Electron Microscope.
Relaxation time (T1) measurements were obtained on a Bruker mq60 minispec NMR
spectrometer at 60 MHz and 37 °C. Fluorescence spectra were obtained using a HORIBA Jobin
Yvon Fluoromax-4 spectrofluorometer. Sonication was performed using a FS60H sonicator
(Fisher Scientific). Centrifugation was performed using a mini-centrifuge (05-090-100, Fisher
Scientific) at 6600 rpm. Vortexing was done using a vortex mixer (Fisher Scientific). Spin
filtration of amyloid protein was performed using SpinX 8161 (Costar) spin filters (0.22 µm).
Rotating of β-amyloid samples was done using a Thermo Labquake Tube Shaker/Rotator.
Inductively coupled plasma mass spectrometry (ICP–MS) analyses were performed by Columbia
Analytical Services Inc, Tucson, Arizona, USA.

Relaxivity measurements of 2.1 and GdIIIDTPA
Longitudinal relaxation times (T1) were measured using a standard recovery method with
a Bruker Minispec mq 60 at 1.4 T and 37 °C in PBS. The slope of a plot of 1/T1 vs concentration
of GdIII was used to obtain relaxivity. Measurements were repeated 3 times with independently
prepared samples, and Gd concentrations were determined by ICP–MS. T1 measurements of
complex 2.1 are given in the Tables 3.1–3.3 for six different concentrations of GdIII (0–0.63
mM). Linear plots obtained by plotting 1/T1 vs concentration for each trial are shown in Figures
3.3–3.5. T1 measurements of GdIIIDTPA are given in the Tables 3.4–3.6 for four different
concentrations of GdIII (0–1 mM). Linear plots obtained by plotting 1/T1 vs concentration for
each trial are shown in Figures 3.6–3.8.
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Table 3.1 Relaxivity measurements of 2.1
(trial 1).
Concentration (mM)
0.63
0.32
0.16
0.08
0.04
0.00

T1 (s)
0.1137
0.2380
0.4959
0.8838
1.5010
3.8600

Table 3.2 Relaxivity measurements of 2.1
(trial 2).

1/T1 (s–1)
8.80
4.20
2.02
1.13
0.67
0.26

Concentration (mM)
0.63
0.32
0.16
0.08
0.04
0.00

T1 (s)
0.1141
0.2350
0.4902
0.8915
1.4350
3.8460

1/T1 (s–1)
8.76
4.26
2.04
1.12
0.70
0.26

Table 3.3 Relaxivity measurements of 2.1 (trial 3).
Concentration (mM)
0.63
0.32
0.16
0.08
0.00

T1 (s)
0.1135
0.2450
0.4915
0.8898
3.8650

1/T1 (s–1)
8.81
4.08
2.03
1.12
0.26

10

10

y = 13.58x + 0.07
R² = 0.998

1/T1 (s–1)

1/T1 (s–1)

y = 13.63x + 0.06
R² = 0.997

0

0
0

GdIII concentration (mM)

0.7

Figure 3.3. Relaxivity plot of complex 2.1
(trial 1).

0

GdIII concentration (mM)

0.7

Figure 3.4. Relaxivity plot of complex 2.1
(trial 2).
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y = 13.67x + 0.01
R² = 0.995
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GdIII concentration (mM)

Figure 3.5. Relaxivity plot of complex 2.1 (trial 3).

Table 3.4 Relaxivity measurements of
GdIIIDTPA (trial 1).
Concentration(mM)
1.00
0.50
0.25
0.00

T1 (s)
0.2846
0.5315
0.9055
3.8500

Table 3.5 Relaxivity measurements of
GdIIIDTPA (trial 2).

1/T1 (s–1)
3.51
1.88
1.10
0.26

Concentration(mM)
1.00
0.50
0.25
0.00

T1 (s)
0.2865
0.5384
0.9366
3.8460

1/T1 (s–1)
3.49
1.86
1.07
0.26

Table 3.6 Relaxivity measurements of GdIIIDTPA (trial 3).
Concentration(mM)
1.00
0.50
0.25
0.00

T1 (s)
0.2726
0.5373
0.9344
3.8470

1/T1 (s–1)
3.67
1.86
1.07
0.26

4

4

y = 3.23x + 0.26
R² = 1

1/T1 (s–1)

1/T1 (s–1)

y = 3.41x + 0.22
R² = 0.9989

0

0
0

GdIII concentration (mM)

1

Figure 3.6. Relaxivity plot of GdIIIDTPA
(trial 1).

0

GdIII concentration (mM)

1

Figure 3.7. Relaxivity plot of GdIIIDTPA
(trial 2).
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Figure 3.8. Relaxivity plot of GdIIIDTPA (trial 3).

Preparation of β-amyloid fibrils
β-Amyloid peptide (1–42) (1 mg, 0.2 µmol) was dissolved in PBS (1 mL) and stirred gently
(350 rpm) at 37 ºC for 20 h to obtain a 0.2 mM stock solution of β-amyloid fibrils following
published procedures.100,104,119
Transmission electron microscopy (TEM) studies
Aggregated β-amyloid peptide was centrifuged (0.2 mM, 100 µL), and the resulting sediment
was suspended in water (20 µL) and mixed by vortexing. Aggregated protein solution (5 µL) was
applied to a TEM substrate grid (200-mesh copper grid coated with Formvar/carbon film) and
incubated for 10 min. Excess solution was removed with a filter paper. Phosphotungstic acid (1%
(w/v), 3 µL) was applied to the grid containing protein. After incubation for 3 min, excess stain
was washed with water (20–40 µL), and excess water was removed with a filter paper. The
resulting sample was air dried for 3 h. TEM was performed at 100 kV (60,000×). The TEM
image (Figure 3.9) of aggregated fibrils is similar to the appearance of other reported TEM
images of aggregated fibrils.100,119
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Figure 3.9. TEM image of β-amyloid aggregates.

Dynamic light scattering (DLS) studies of fibril formation
A 100 µL aliquot was taken from the β-amyloid stock while stirring and filtered through
a 0.22 µm spin filter to remove large aggregates. The filtered solution was transferred to a
disposable microcuvette (40 µL) and measured for size distribution by collecting data at a 173º
measurement angle on a Zetasizer NanoZS instrument at 24.9 ºC (dispersant refractive index =
1.332, and viscosity = 0.9128 cP). Size distribution data obtained from DLS based on intensity
(Figure 3.10) provide evidence for the presence of fibril aggregates with diameters of 200–600
nm that are comparable to the sizes of aggregates reported in other studies.120
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Figure 3.10. Dynamic light scattering distribution data of β-amyloid aggregates (intensity
distribution).

Binding studies between conjugate 2.1 and amyloid fibrils
Aliquots (0, 25, 50, and 100 µL) were taken from the stirring stock solution of β-amyloid
aggregates and mixed with conjugate 2.1 (0.1 mM, 100 µL). The total volume of each sample
was brought to 200 µL with PBS. Samples were vortexed (~5 s) and incubated at ambient
temperature with rotation for 3 h. β-Amyloid (0, 25, 50, and 100 µL) was mixed with PBS to a
total volume of 200 µL, vortexed (~5 s), incubated with rotation for 3 h, and used as the control.
GdIIIDTPA (0.1 mM, 100 µL) was used as the non-specific control, and samples with GdIIIDTPA
were prepared following the same procedure as for conjugate 2.1. At the end of the incubation
T1 relaxation times were measured for each sample (Table 3.7). Measurements were triplicated
with independently prepared samples for complex 2.1 and measurements were duplicated for
control samples. Fluorescence emission of samples was measured at the end of the relaxation
time measurement. Samples were excited at 385 nm with a slit width of ±10 nm.
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Table 3.7 β-Amyloid (βA) binding T1 measurements

Sample
2.1/βA (trial 1)
2.1/βA (trial 2)
2.1/βA (trial 3)

T1 (ms) at the following ratios of
complex to βA*
(1:2)
(1:1)
(1:0.5)
(1:0)
1267
1302
1339
1388
1265
1298
1395
1375
1262
1321
1328
1380

GdDTPA/βA (trial 1)
GdDTPA/βA (trial 2)

2225
2232

2243
2247

2247
2243

2253
2253

3826
3822
3835
3865
βA control (trial 1)
3815
3850
3830
3860
βA control (trial 2)
*The concentration of βA in the βA control trials is the same as in the
samples containing 2.1 and GdDTPA at the same ratios.

Conclusion
An efficient, small molecular probe for β-amyloid aggregates from non-toxic curcumin
and a derivative of a clinically approved contrast agent for MRI was synthesized. In vitro studies
demonstrate that curcumin-conjugated contrast agent 2.1 interacts with β-amyloid aggregates
resulting in a shortening of T1 and change in the wavelength and intensity of fluorescence
emission. While future studies related to imaging and pharmacokinetic delivery are necessary to
evaluate the utility of this work in vivo, the multimodal nature of imaging agent 2.1 is important
for Alzheimer’s disease related research. In addition, we expect that the facile synthesis of the
curcumin-amine linker will be a powerful tool for the synthesis of other curcumin conjugates that
are stable in biological environments.
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CHAPTER 4. A myelin-specific, multimodal imaging agent for magnetic resonance,
optical, and mass spectrometric imaging.
Introduction
The ability to view changes in the brain and peripheral nervous system is of great
importance to the study of neurodegenerative diseases and aging,121–124 and among the
components of the nervous system, myelin is a critical target for understanding neuronal
anatomy and function.125–127 Myelin is a characteristic lipid-protein membrane in the nervous
system that aids with the proper conduction of nerve impulse. Consequently, nerve cell
deterioration caused by inherited or acquired neuropathologies and brain injuries often changes
myelinated nerve structures.125 Hence, effective monitoring of the morphology of myelinated
regions of the brain is important in the study of neurodegenerative diseases and therapies for
these diseases.
Histology using optical microscopy with chromophoric or fluorophoric stains was the
primary method of imaging myelin until recently.126,127 Advancements in imaging technologies
have permitted the use of other modalities for imaging myelin including positron emission
tomography (PET) and magnetic resonance imaging (MRI). Although several PET tracers that
target myelin have been reported,122,128,129 the use of PET for imaging myelinated structures in
brain is limited because of its low (1–2 mm) resolution.6,122 Currently, the most promising nonoptical imaging method for myelin is MRI.38,39,122,123,125 The ability to acquire whole brain
images using MRI with high resolution (25–100 µm)6 is important for in vivo imaging and ex
vivo pre-clinical research. Various nonconventional and indirect MRI techniques have been
investigated for imaging myelin including magnetization transfer, diffusion tensor imaging, T2
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relaxometry, and ultrashort echo time MRI.123,125 But, the specificity of these methods for myelin
is not ideal, and these methods struggle to distinguish changes in myelination from hemorrhages,
iron deposits, and changes in the water content of tissue.
Myelin-specific contrast agents provide a way to augment the lack of specificity in
myelin imaging; however, the three myelin-specific contrast agents for MRI that have been
reported are limited by low relaxivity values.38,39,81,130 Myelin-specific GdIII-containing small
molecules were reported that are similar in efficiency (5.1 mM–1 s–1) to nonspecific clinically
approved contrast agents.38,39,130 These contrast agents were able to highlight myelination in MRI
via T1 maps; however, the images acquired with these agents demonstrate the need for contrast
agents with higher relaxivities to produce images of myelinated structures with increased signal
to noise ratios.38,39,130 Further, the CuII-containing myelin-specific histology stain Luxol fast blue
MBS (LFB MBS) was reported for imaging of myelinated brains with magnetic resonance
spectroscopy.81 However, LFB MBS did not produce appreciable contrast because of the
extremely low efficiency (0.09 mM–1 s–1) of the complex as a contrast agent for MRI.81
Investigation of efficient myelin-specific agents for contrast-enhanced MRI is crucial for
effective visualization of changes in brain tissues.
Sensitive measurements of changes in tissue structure require high precision and
accuracy, and one way to ensure the reliability of findings is with verification using orthogonal
imaging techniques. Furthermore, the ability to combine techniques that produce high resolution
structural images with techniques that yield chemical information enables the extraction of
multiple types of information from a single tissue sample. Multimodal myelin-specific imaging
agents would meet this need by allowing effective visualization of the distribution of myelin and
the chemical composition of the agent. In this research, a new multimodal myelin-specific
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contrast agents that are more efficient than clinically approved contrast agents for MRI and that
can be used with light and near-IR fluorescence microscopies and mass spectrometric imaging
were reported. We also report the imaging of myelinated structures in ex vivo samples using our
new agents.
Materials and Methods
A detailed description of the synthesis and characterization of GdIII-containing texaphyrins 2.2–
2.6 is described in the Chapter 2.
Animals. Animal care and use were in accordance with the National Institutes of Health Animal
Care Guidelines and approved by the Wayne State University Institutional Animal Care and Use
Committee. Intact brain tissue used for the section- and en bloc-staining techniques were
obtained from euthanized C57Bl/6 mice that were bred in-house.131 Prior to euthanizing, all
efforts were made to minimize suffering. The approval from Institutional Animal Care and
Approval Committee to handle mice in Prof. Conti Alana’s lab is included in Appendix C.
Stain Preparation. Texaphyrin stain 2.2: To a mixture of ethanol (95%, 2 mL) and acetic acid
(10%, 100 µL) was added texaphyrin 2.2 (4.4 mg, 0.0045 mmol, 1 equiv). The reaction mixture
was heated at 60 °C for 18 h, cooled to ambient temperature, and filtered through a 0.2 µm filter
to obtain stain 2.2 as a dark green solution. The stain solution was stored at 4 °C. The
concentration of the stain solution was determined by ICP–OES.
Texaphyrin stain 2.3: To a mixture of ethanol (100%, 2 mL) and acetic acid (10%, 100 µL) was
added texaphyrin 2.3 (4.0 mg, 0.0048 mmol, 1 equiv) followed by ditolylguanidine (4.7 mg,
0.019 mmol, 4 equiv) dissolved in acetic acid (1 M, 19 µL, 4 equiv). The reaction mixture was
filtered through a 0.2 µm filter and heated at 60 °C for 18 h. The solution was cooled to ambient

78

temperature, and filtered through a 0.2 µm filter to obtain stain 2.3 as a dark green solution. The
stain solution was stored at 4 °C. The concentration of the stain solution was determined by ICP–
OES.

Texaphyrin stain 2.4: To a mixture of CH3OH/water (3:2 v/v, 1 mL) was added texaphyrin 2.4
(4.2 mg, 0.0045 mmol, 1 equiv) followed by ditolylguanidine (4.4 mg, 0.018 mmol, 4 equiv)
dissolved in acetic acid (1 M, 18 µL, 4 equiv). The reaction mixture was heated at 60 °C for 6 h.
The solution was cooled to ambient temperature, and the solvent was removed under reduced
pressure. The residue was dissolved in a mixture of ethanol (95%, 2 mL) and acetic acid (10%,
100 µL), and the solution was heated at 60 °C for 14 h. The solution was cooled to ambient
temperature and filtered through a 0.2 µm filter to obtain stain 2.4 as a dark green solution. The
stain solution was stored at 4 °C. The concentration of the stain solution was determined by ICP–
OES.

Texaphyrin stain 2.5: To a mixture of CH3OH/water (1:1 v/v, 1 mL) was added texaphyrin 2.5
(4.1 mg, 0.0041 mmol, 1 equiv) followed by ditolylguanidine (6.0 mg, 0.025 mmol, 6 equiv)
dissolved in acetic acid (1 M, 25 µL, 6 equiv). The reaction mixture was heated at 60 °C for 6 h.
The solution was cooled to ambient temperature, and the solvent was removed under reduced
pressure. The residue was dissolved in a mixture of ethanol (95%, 2 mL) and acetic acid (10%,
100 µL), and the solution was heated at 60 °C for 14 h. The solution was cooled to ambient
temperature and filtered through a 0.2 µm filter to obtain stain 2.5 as a dark green solution. The
stain solution was stored at 4 °C. The concentration of the stain solution was determined by ICP–
OES.
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Texaphyrin stain 2.6: To a mixture of CH3OH/water (1:2 v/v, 1 mL) was added texaphyrin 2.6
(4.2 mg, 0.0038 mmol, 1 equiv) followed by ditolylguanidine (8.0 mg, 0.033 mmol, 8 equiv)
dissolved in acetic acid (1 M, 33 µL, 8 equiv). The reaction mixture was heated at 60 °C for 6 h.
The solution was cooled to ambient temperature, and the solvent was removed under reduced
pressure. The residue was dissolved in a mixture of ethanol (95%, 2 mL) and acetic acid (10%,
100 µL), and the solution was heated at 60 °C for 14 h. The solution was cooled to ambient
temperature and filtered through a 0.2 µm filter to obtain stain 2.6 as a dark green solution. The
stain solution was stored at 4 °C. The concentration of the stain solution was determined by ICP–
OES.

Tissue Staining. Tissue Preparation. Formaldehyde (37% wt/v), Li2CO3, ethanol (200 proof),
and agarose were purchased from Sigma Aldrich, Acros Organics, Decon Laboratories. Inc., and
OmniPur, respectively. Tissues were acquired within 5 min of animal sacrifice and placed in a
beaker of 3.7% (wt/v) aqueous formalin solution. Fixed tissue was stored at 4 °C in formalin.
Prior to staining, fixed tissues were removed from formalin storage and rinsed with purified
water (~10 mL) to remove formalin.
Section-Staining Procedure. Tissue sections (200 µm thick) were obtained from fixed intact
tissues using a vibrotome 3000 (MyNeuroLab). For each stain, three tissue sections were stained
that provided observation of a diverse assortment of brain regions: 0.50 to 1.54, 0.14 to –0.58,
and –1.58 to –2.18 mm from Bregma.132 Each tissue sample was incubated in staining solution
(2–0.8 mM, 0.2 mL) for 5 h at 54 °C. Tissue sections were removed from the staining solution
and rinsed by swirling with ethanol (95%, 1 mL, 1 min) followed by water (1 mL, 1 min).
Tissue stained with texaphyrin 2.2 were differentiated with a solution of Li2CO3 (4.5 mM) in
ethanol (65%, 4 mL) for 30 min, three concentrations of ethanol (100, 95, and 70%, 4 mL each)
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for 45 min each, and water (4 mL) for 5 min. All differentiations and rinsings were performed on
a rotator (Thermo Labquake Tube Shaker/Rotator). Tissues stained with texaphyrins 2.3–2.6
were differentiated with a solution of Li2CO3 (4.5 mM) in ethanol (65%, 4 mL) for 1–2 h, rinsed
with ethanol (95%, 4 mL, 1 min), and hydrated in water (4 mL, 5 min for complexes 2.3 and 2.4,
1 min for complexes 2.5 and 2.6). At the end of the differentiation and hydration, each tissue
section was mounted on a microscope slide for imaging.
En bloc-Staining Procedure. Intact mouse brains were incubated in solutions of texaphyrin 2.4
(0.8 mM, 1.8 mL) for 24 h at 54 °C. At the end of the incubation, the brains were rinsed with
ethanol (95%, 25 mL, 1 min) then water (25 mL, 1min). The brain tissue was pat dried with
tissue paper, and an incision was made using a scalpel along the midline on the dorsal face of the
intact brain, such that the incision reached the dorsal third ventricle. Brains were placed in a
solution of Li2CO3 (11 mM) in ethanol (40%, 25 mL) and the vial containing the brains in the
Li2CO3 solution was rotated. The solution of Li2CO3 was changed after 6 and 24 h, and the
differentiation was continued for total of 65 h. At the end of the differentiation, the mouse brain
was rinsed with water (25 mL, 1 min) and hydrated in water (25 mL) for 10 min. The hydrated
brain was pat dried and suspended in agarose gel (2%) for MR imaging.
Optical Imaging. Optical images were acquired using an Olympus SZX7 (model number SZ2ILST) microscope (1.25× or 5.6× magnification) with an attached SPOT idea microscope camera
(model number 27.2–3.1 MP). Differentiated section-stained mouse brain tissue samples were
mounted on microscope slides to obtain images. En bloc-stained mouse brains were sliced (200
µm) using the vibrotome after obtaining MR images, and the slices were mounted on microscope
slides to obtain images.
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MR Imaging. MR Imaging. MRI scans were performed with a 7 T Varian small animal MRI
scanner (299.44 MHz, 7.0 T) equipped with a 12 cm bore magnet and a 38 mm diameter
homemade transmit/receive quadrature birdcage coil. Samples included a mouse brain stained
with texaphyrin 3 and an unstained control mouse brain suspended in agarose. T1-maps were
acquired at ambient temperature using a T-One by Multiple Read-Out Pulses,133 which is a
Look–Locker sequence.134 At least one dummy cycle (N pulses followed by Trelax) was applied
before the start of data acquisition.

Inversion of the longitudinal magnetization was

accomplished using a non-selective hyperbolic secant adiabatic pulse of duration 12 ms. One
phase-encode line of 40 small-tip-angle (approximately10° 3-lobe sinc shaped pulses) gradientecho images (4 ms) was acquired after each such adiabatic inversion (50 ms intervals) for a total
recovery time of 3000 ms with a 3 s relaxation interval between each adiabatic inversion.
Matrix size = 256×192; 32 mm2 field-of-view; three image slices at 0.5 mm thickness; and eight
averages. Analysis proceeded as described previously,135 with a modification that is now
described.

Because the 3 s relaxation time was not sufficient to allow the longitudinal

magnetization to re-equilibrate after inversion, the equilibrated magnetization of the sequence
was iteratively estimated along with the other model parameters (proton density, T1, and tipangle). ImageJ was used to process the R1-maps. Brightness and contrast were adjusted to 50 and
color balance was adjusted to 244. Five regions of interest were used to calculate the percent
increase of R1 in myelin-rich regions with respect to myelin-poor regions in the stained and
unstained brains (Figure B.26). The difference between the average R1 values of the regions of
interest from myelin-rich and myelin-poor regions were used to calculate percent increase of R1.
Laser Spray Ionization Vacuum (LSIV) Mass Spectrometric Imaging. Mouse brain tissue
(200 µm) mounted on microscope slide was spray coated with the matrix 2-nitrophloroglucinol
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(2-NPG) (Alfa Aesar) using an air brush (Iwata). A commercial matrix-assisted laser desorption
ionization (MALDI) source of a SYNAPT G2 mass spectrometer (Waters Corporation) was used
for the imaging. The intermediate source pressure was 0.16 Torr. The laser used was an Nd:YAG
laser (355 nm) in reflection geometry mode with a laser power of 12.5 J cm–2 and a firing rate of
200 Hz. Data were acquired

in positive ion and sensitivity modes. Laserspray ionization

settings were used and are as follows: 0 V on sample plate; 10 V “extraction”; 10 V “hexapole
bias”; 5 V “aperture 0”. Data were processed using MassLynx version 4.1. Mass spectra were
converted to MSI files using a MALDI Imaging Converter. The location of the signal of the
complex was mapped using BioMAP 3.8.0.1 from Novartis Institutes for Biomedical Research,
Basel, Switzerland.
Results
The design of myelin-specific contrast agents used in this research was inspired by the
myelin-specific histology stain LFB MBS (Figure 4.1). The structural features of LFB MBS
were mimicked to synthesize a ligand with a cavity large enough to encapsulate a GdIII ion for
efficient MRI enhancement. The mimic contains a texaphyrin, a ligand that is structurally similar
to the phthalocyanine ligand of LFB MBS (Figure 4.1). Although it is known that LFB MBS
interacts with myelin, the site of interaction is not well established; however, the currently
accepted hypothesis assumes that the sulfonate groups of LFB MBS interact with myelin basic
protein.126 To understand the features that are important for interaction with myelin, five GdIIIcontaining texaphyrins that vary in functional group identity were synthesized (2.2–2.6 in Figure
4.1).
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Figure 4.1. Chemical structures of LFB MBS and GdIII-texaphyrin complexes 2.2–2.6.

The functional groups introduced to the texaphyrin periphery include sulfonates,
carboxylates, and methyl esters. Although many texaphyrin derivatives have been reported,
texaphyrins 2.2–2.6 were new derivatives. Sulfonates and carboxylates were used to test the
importance of the identity of acidic functional groups for interaction with myelin, and methyl
esters were used as a control to study the need of acid functional groups. Incorporation of
different types and numbers of functional groups into the periphery of texaphyrins resulted in
different physicochemical properties including polarity and solubility.

Solubility of texaphyrins 2.2–2.6
The solubilities of texaphyrins 2.2–2.6 after the preparation of stain solutions are
described here. Complexes 2.2, 2.3, and 2.4 were sparingly soluble in water but soluble in
methanol, ethanol, and acetonitrile, while complexes 2.5 and 2.6 were soluble in water.
Texaphyrins 2.2 and 2.4–2.6 were soluble in mixtures of water and these organic solvents and
solutions of 2.2 and 2.4–2.6 did not yield precipitate after 3 months; however, texaphyrin 2.3
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produced an insoluble precipitate in the presence of 95% ethanol 15 min after dissolution. The
use of absolute ethanol avoided the rapid precipitation of 2.3, but upon storage, precipitation was
observed after 2 days. Therefore, stain 2.3 was prepared fresh for each experiment.

Properties of texaphyrins 2.2–2.6 that are important for imaging
The extended conjugation of texaphyrins produces a characteristic sharp absorption in the
visible region that causes the metal complexes to appear dark green in color. All five texaphyrin
complexes demonstrated similar absorptions (Figure B.5) regardless of the number or type of the
functional groups on the side chains. The deep green color of the texaphyrin complexes enabled
the visualization with light microscopy similar to the visualization of the blue histology stain
LFB MBS. The fluorescence emissions of the five complexes were also similar to each other
regardless of functional group identity (Figures B.6 and B.7), exhibiting near-IR emission when
excited by 468–492 nm light.
The efficiency of complexes 2.2–2.6 as contrast agents for MRI was determined by
measuring their relaxivities at 1.4 T and 37 °C using solvent systems that permit sufficient
solubility for the complex. The solvent system that was used for the dissolution of the complex
was measured as the blank in each case. All five complexes demonstrated higher relaxivity
values than current clinical contrast agents for MRI (Table 4.1, Tables B1–15, and Figures B.8–
B.22). Texaphyrin 2.2 had the highest relaxivity (19.5 mM–1 s–1) and was similar to other
reported texaphyrins with neutral functional group-containing side chains.136 Texaphyrins 2.3–
2.6 that contain negatively charged acidic functional groups in their side chains demonstrated
lower relaxivities than 2.2, but more than 3-fold higher values than clinically approved contrast
agents.
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Table 4.1. Relaxivity values of texaphyrin complexes 2.2–2.6.
GdIIItexaphyrin
complex

2.2

2.3

2.4

2.5

2.6

Relaxivity
(mM–1 s–1)

19.5 ± 0.1*

13.3 ± 0.2*

11.6 ± 0.1†

11.3 ± 0.2

11.7 ± 0.1

Relaxivity measured at 1.4 T, 37 °C, and in water or *30% or †50% methanol in water. Results
are reported as mean ± standard error of three independently prepared samples.

While the electronic properties of GdIII produce contrast enhancement with MRI, the
unique isotopic distribution of GdIII (Figure B.23) enables identification of GdIII-containing
texaphyrins by mass spectrometry even in the presence of complex mixtures like tissue sections.
Hence, the localization of texaphyrins in stained tissue can be mapped using mass spectrometry.

Staining tissue with texaphyrins 2.2–2.6
The staining of mouse brain tissue was performed by incubating tissue samples (200 µm
thick) in stain solutions at 54 °C for 5 h. At the end of the incubation, a marked reduction of the
intensity of color of the stain solution was visible, and the mouse brain sections were green.
When comparing texaphyrin stains 2.2–2.6 to each other, the staining solution of complex 2.2
demonstrated the lowest reduction of color after incubation and resulted in only lightly colored
tissue. Tissue sections stained with texaphyrins 2.3–2.6 were dark green. To differentiate stained
tissue samples, solutions of Li2CO3 were used; however, the use of aqueous Li2CO3 that is used
with LFB MBS126 led to under-differentiation for tissue samples stained with texaphyrins 2.3
and 2.4 and over-differentiation for texaphyrins 2.5 and 2.6. An ethanolic Li2CO3 solution was
selected as the optimal differentiation solution because it demonstrated appreciable
differentiation for texaphyrins 2.3–2.6.
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Texaphyrin 2.2 that contains methyl esters did not differentiate with aqueous or ethanolic
Li2CO3. Because of the inability to differentiate myelinated and non-myelinated regions with
texaphyrin 2.2, it was not used for further studies.Texaphyrins 2.3 and 2.4 provided a visible
differentiation of myelinated regions from non-myelinated regions, and texaphyrins 2.5 and 2.6
were removed completely from tissue upon exposure to water. The removal of stain with
exposure to water likely due to the increased hydrophilicity from presence of three or more
negatively charged sulfonate groups and is an undesirable feature for ex vivo staining of myelin.
In contrast, texaphyrins 2.3 and 2.4 differentiated with ethanolic Li2CO3 and were stable upon
exposure to water; thus, texaphyrins 2.3 and 2.4 were found to be viable candidates for staining
myelin. Myelin-rich white matter regions demonstrated a green color with respect to myelin-poor
surrounding tissues in coronal brain sections with light microscopy when stained with
texaphyrins 2.3 and 2.4. Specifically, the myelin-rich corpus callosum, striations in the caudate
putamen, anterior commissure, and mammillothalamic tract appeared green in the optical images
(Figures 4.2, and 4.3).
Texaphyrin 2.4 was used for staining intact mouse brains for MRI studies because of its
ability to differentiate myelinated structures and the ease of handling without precipitation.
When staining intact brains, the optimal incubation time for the diffusion of the texaphyrin was
found to be 24–26 h. The diffusion of large molecules like texaphyrins takes more time for thick
tissue samples than thin tissue sections. The differentiation time for intact brain was 65 h, and an
incision along the mid line of the brain was made prior to differentiation to facilitate the
diffusion of Li2CO3 into the tissue. The long differentiation times and mechanical opening of
tissue were necessary for penetration of ionic Li2CO3 through hydrophobic tissue layers.
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Differentiated whole mouse brain was used for MR imaging to investigate the ability of
texaphyrin 2.4 to act as a myelin-specific contrast agent.

Figure 4.2. Optical images of texaphyrin-stained mouse brain slices. Columns A–C contain
images of representative mouse brain samples from three different regions of the brain (A, 0.50
to 1.54; B, –1.58 to –2.18; and C, 0.14 to –0.58 mm from Bregma132) that were treated with
texaphyrin complexes 2.2–2.6. Slice thickness = 200 µm, and scale bar = 1 mm.
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Figure 4.3. Optical images of mouse brain sections stained with texaphyrin 2.4. Panel a. shows
representative brain images from 1.54 to –1.82 mm from Bregma.132 Panel b. shows high
magnification images of myelinated regions and the magnified area is represented with black
squares in panel a. Myelin rich regions, namely; forceps minor of the corpus callosum in 1;
external capsule and part of the caudate putamen in 2; fornix and anterior commissure anterior
part in 3; and the mammillothalamic tract in 4 are highlighted in green. Slice thickness = 200
µm, and scale bars = 1 mm.

Mass spectrometric imaging of texaphyrin 2.4 stained mouse brain
The brain sample stained with texaphyrin 2.4 was imaged with LSIV mass spectrometric
imaging. Samples for mass spectrometric imaging were prepared by spray coating the brain
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sections with the matrix 2-nitrophloroglucinol. Application of 2- nitrophloroglucinol facilitates
ionization of the texaphyrin complexes. Expected m/z for intact texaphyrins were detected in the
tissue. The regions with high relative concentrations of texaphyrins corresponded to myelin-rich
regions of the brain sample (Figure 4.4).

Figure 4.4. Left, Mouse brain atlas corresponding to a matching coronal section with prominent
myelin-rich regions highlighted in green (adapted from reference 137); Right, LSIV mass
spectrometric imaging of mouse brain sample stained with texaphyrin 2.4. Relative concentration
of the texaphyrin 2.4 in myelin-rich regions is higher with respect to myelin-poor regions in the
mass spectrometric image.

MRI imaging of texaphyrin 2.4 treated mouse brain
An intact mouse brain stained with texaphyrin 2.4 and an unstained control brain were
embedded in agarose prior to MR imaging. The T1-maps of the mouse brains stained with
texaphyrin 2.4 demonstrated a clear deference between myelin-rich (dark) and poor (bright)
regions in comparison to the unstained control (Figure 4.5, a and b). Myelin-rich regions of the
stained sample were dark because the T1-relaxation time is shorter (~400 ms) than the myelin
poor regions (~650 ms) of the same tissue and the T1 relaxation time of the control sample
(myelin-rich regions ≈ 1000 ms and myelin-poor regions ≈ 1300 ms). The T1-map was converted
into an R1-map because it is easier for visualization of regions of interest (Figure 4.5, c and d).

90

Figure 4.5. Representative T1- and R1-maps of coronal sections of mouse brains (–1.58 mm from
Bregma)132: a. T1-map of unstained control brain; b. T1-map of mouse brain stained with
texaphyrin 2.4; c. R1-map of unstained control brain; and d. R1-map of texaphyrin 2.4 stained
mouse brain. Myelin-rich regions of stained brain sample look brighter with respect to the
myelin-poor gray matter regions of the tissue, and myelin-rich regions of the control in the R1map.
R1 values represent 1/T1, and short T1 values produce large R1 values thus, inverting the
brightness of the T1-map. The R1 value of myelin-rich regions of the stained brain was ~2.6 fold
greater than the surrounding myelin-poor tissue while the R1 value was only ~1.6 fold greater in
the myelin rich regions of the unstained control brain. Thus, the myelin-rich regions in R1-map of
stained brain look brighter and are easy to distinguish due to the additional contrast enhancement
by texaphyrin 2.4 with respect to the unstained control. At the end of the MR imaging, the brain
sample was sectioned and observed with light microscopy and mass spectrometric imaging to
verify the MRI and to identify the chemical identity of the Gd III-containing contrast agent after
staining (Figure 4.6 and Figure B.25).
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Figure 4.6. Optical and mass spectrometric images of coronal brain sections corresponding to
the MR images in Figure 4.5. a. optical image of unstained control brain; b. optical image of
brain stained with texaphyrin 2.4; c. mass spectrometric image of brain stained with texaphyrin
2.4; d. mouse brain atlas corresponding to a matching coronal section with prominent myelinrich regions highlighted in green (adapted from reference 137). In the image cc, CPu, f, fi, ic,
mmt, and ot stand for corpus callossum, caudate putamen, fornix, fimbria, internal capsule,
mammillothalamic tract, and optic tract, respectively. Red arrows point to the myelin-rich
regions of mass spectrometric image. Scale bar = 1 mm.

Discussion
A well known myelin-specific histology stain LFB MBS was used as our structural
inspiration because it contains a metal-ligand motif that is amenable to adaptation into a contrast
agent for MRI. However, the ligand framework of LFB MBS cannot be directly used for the
synthesis of stable GdIII-containing complexes because the cavity size of the phthalocyanine in
LFB MBS does not match well with the ionic radius of GdIII.138 Sessler and co-workers reported
the use of expanded porphyrins known as texaphyrins to form stable complexes with
lanthanides.82–84, 93–95 Their studies with GdIII-containing texaphyrins have shown that complexes
of these macrocycles are efficient contrast agents for MRI and have higher relaxivities than
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clinically approved contrast agents.136 Knowledge from Sessler’s studies helped to realize that
texaphyrins have the potential to mimic the structural features of phthalocyanine— including a
planar aromatic macrocycle, acidic functional groups, and charge—while forming stable
complexes with GdIII. Although, LFB MBS interacts with myelin, the important structural
features for interaction are not well established. Therefore, five different texaphyrin complexes
that vary in the type and number of functional groups on the side chains were synthesized. This
variety was expected to enable on understanding of the structural features that lead to
interactions with myelin. The functional groups that were selected included methyl esters,
sulfonates, and carboxylates. Because some of these functional groups have not been reported
with texaphyrins, synthetic routes to make them had to be devised.
The functional group selection allowed to explore the influence of a variety of properties
on staining. Complex 2.2 has an overall charge of +2, and it does not have acidic functional
groups; thus, it was designed to test if negative charge or acidic functional groups are crucial for
myelin-specific interactions. Complex 2.3 has carboxylate groups and is neutral. This complex is
a carboxylate analogue for sulfonate containing texaphyrins and was synthesized to study the
necessity of sulfonates as the acidic functional groups. Complexes 2.4–2.6 have sulfonate groups
and charges of 0, –1, –2, respectively, and these complexes were designed to study the effect of
the number of sulfonate groups on interaction with myelin.
Initial staining studies with coronal sections of mouse brain tissue was performed to
visualize the interaction of texaphyrins 2.2–2.6 with myelinated structures. Brain sections stained
with GdIII-containing texaphyrins were differentiated with Li2CO3 solutions to remove excess
and loosely bound texaphyrins, under the assumption that mild alkali solutions interrupt the
interaction between sulfonates and myelin.126 Because hydrophilic alkali solutions do not enter
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the hydrophobic domains of myelin to interrupt the interactions, the stain is retained in
myelinated structures.126 Because of the optical absorptions of texaphyrins, light microscopy
was initially used to gauge the interaction of the texaphyrins with myelin. Texaphyrin complexes
have a characteristic dark green color due to the absorption of visible light in the 700–750 nm
range. Thus, texaphyrins are chromophoric probes similar to LFB MBS. Additionally, the
fluorescence emission studies demonstrated a near-IR emission and, consequently, the potential
for use as fluorescence probes.
Light microscopy images of mouse brain slices stained with Gd III-containing texaphyrins
showed that complexes 2.3 and 2.4 that are less hydrophilic than complexes 2.5 and 2.6
differentiate better and, consequently, highlight myelinated regions in the brain tissue more
efficiently than the other three complexes. Texaphyrins 2.5 and 2.6 that have more than two
negatively charged functional groups did stain myelin, but the high solubility of these
texaphyrins in water interferes with the retention of the stain in myelinated regions. Texaphyrin
2.2 did not highlight myelin and demonstrated non-specific staining of brain tissue. Unlike
texaphyrins 2.3–2.6, Li2CO3 was not able to remove texaphyrin 2.2 from tissue samples. The
observations with staining studies of texaphyrins 2.2–2.6 reveal that the presence of a negatively
charged acidic functional group is vital for interaction with myelin. It is assumed that the
interaction of LFB MBS and myelin occurs through an acid-base type interaction between the
negatively charged sulfonate groups of the stain and positively charged amine residues of the
myelin basic proteins.126 The observations from this research support the presence of this type of
interaction because texaphyrin 2.2 with neutral methyl ester groups did not demonstrate myelinspecific staining of brain tissues.
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The non-specific labeling observed with texaphyrin 2.2 likely arises because the
positively charged molecule interacts with negatively charged lipids in the tissue. Furthermore,
maintaining some hydrophobicity seems to be critical to attain desirable staining and
differentiation. A possible explanation for observations with texaphyrins 2.5 and 2.6 is that the
hydrophilic stain is unable to enter the hydrophobic domains of the myelin sheath. Instead, these
molecules might interact with the surface myelin basic proteins, which would make them easily
remove upon exposure to water.
To confirm the staining pattern observed with light microscopy and to explore the
integrity of the chemical composition of texaphyrins after undergoing staining and
differentiation, mass spectrometric imaging was performed with brain slices stained with
texaphyrins 2.2–2.6. Although, mass spectrometry has been used as a tool for the
characterization of compounds for decades, it has not been used as a tool of imaging until
recently.139 Several promising imaging studies using MALDI and LSIV have been reported for
imaging tissues via the detection of proteins or lipids.139–141 However, the detection of proteins
and lipids is often difficult because of the high background present in biological samples. Thus,
to confirm the presence of proteins or lipids of interest, a secondary mass spectrometric
technique is usually required. But, when non-endogenous material like a contrast agent is being
imaged, interference from background is avoided.142 Because of characteristic mass distribution
of GdIII with seven major isotopes (Figure B.23), the detection of GdIII-containing texaphyrins in
tissue samples is straight forward. The imaging of brain samples stained with complex 2.4 was
performed with LSIV mass spectrometry. The presence of intact metal complex in tissue samples
indicates the robustness of the metal complex for the staining conditions. The images from brain
tissues stained with texaphyrin 2.4 demonstrated high concentration regions that overlapped with
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the myelin-rich structures of the mouse brain. Thus, confirming the presence of intact complex in
the myelinated structures that were observed with optical microscopy.
From optical microscopy, texaphyrins 2.3 and 2.4 that contain two carboxylates and
sulfonates, respectively, demonstrated better staining of myelinated regions in brain tissues than
texaphyrins 2.2, 2.5, or 2.6. This observation indicates that the negatively charged functional
groups do not need to be sulfonates. However, handling of texaphyrin 2.3 is difficult because of
the formation of precipitate upon storage that results likely due to the oligomerization via
bridging of carboxylates among GdIII. Consequently, texaphyrin 2.4 was selected as the best
myelin-specific texaphyrin of the five complexes for moving to staining of intact brains and
observation with MRI.
Texaphyrins 2.2–2.6 demonstrated 3.5–4× higher relaxivities than clinically approved
contrast agents. These high relaxivities likely result from a combination of slow tumbling due to
the size of the molecule and the availability of more than one site for water coordination. Higher
relaxivity is desirable for contrast agents because it enables efficient contrast enhancement,
which is especially important for detection of fine structures including white matter structures.
The relaxivity of methyl ester-containing texaphyrin 2.2 is 1.8–1.5× greater than the sulfonate
and carboxylate-containing texaphyrins 2.3–2.6, possibly because the interaction of these
negatively charged groups with GdIII

causes

a reduction of the available sites for water

coordination. Ion mobility mass spectrometric studies done with texaphyrin 2.4 have
demonstrated two species in the mass plot with same m/z ratio but different drift times (Figure
B.24). If negatively charged groups interact with the GdIII, those texaphyrins would have a more
compact structure than texaphyrins with free side chains and will result in different drift times.
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R1-mapping of intact mouse brain stained with texaphyrin 2.4 was performed to
investigate the contrast enhancing properties of the complex. Myelinated regions of the R1-map
of the brain samples stained with texaphyrin 2.4 demonstrated a faster relaxation rate (2.6-fold)
than myelin-poor regions of the stained tissue. The enhancement of R1 of the myelin-rich regions
from the surroundings was only 1.6-fold for the unstained control. Water protons tend to relax
faster in the presence of paramagnetic GdIII because of the magnetic inhomogeneity created by
the GdIII center. Thus, the increase of the R1 relaxation rate indicates the presence of GdIII. R1maps are useful for visualizing myelinated structures because of the presence of positive contrast
enhancement in stained regions.
To validate the observations from MRI studies with intact brains, the brain was sectioned
after MR imaging and confirmed the presence of stain with optical microscopy and mass
spectrometric imaging. White matter structures appeared green under the light microscope
(Figure 4.6 and Figure B.25), and LSIV mass spectrometric imaging of the corresponding brain
slice of MRI confirmed that texaphyrin 2.4 was interact and distributed in regions that showed a
positive enhancement in R1-map (Figure 4.5). The imaging studies from orthogonal imaging
modalities confirmed the ability of texaphyrin 2.4 to diffuse into intact mouse brains,
differentiate to be retained specifically in myelinated regions, and to act as a multimodal imaging
agent facilitating the visualization of white matter structures and chemical information about the
structure of the imaging agent after staining.
Conclusion
Efficient, small molecular probes for myelin were synthesized using a structuremimicking strategy. Ex vivo studies demonstrated that texaphyrins 2.3 and 2.4 interact with
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myelin. The optical and magnetic properties of these texaphyrin complexes allowed the imaging
of myelin in brain sections and intact brains using optical microscopy and MRI. Furthermore, the
unique isotopic distribution of GdIII facilitated the use of mass spectrometric imaging of myelin
to provide chemical information regarding the imaging agent in tissue. The myelin-specific
imaging agent 2.4 render the use of MRI, optical, and mass spectrometric imaging to study
myelination and demyelination in mouse models of neuropathologies for pre-clinical research.
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CHAPTER 5. Conclusions and Future Directions
Conclusions
A multimodal, β-amyloid-targeted contrast agent
A β-amyloid-targeted GdIII-containing complex was synthesized using the conjugation
strategy in which a curcumin molecule and a derivative of a clinically approved contrast agent
were conjugated using a short linker. The conjugated complex 2.1 demonstrated a higher
relaxivity than clinically approved contrast agents for magnetic resonance imaging (MRI).
Furthermore, in vitro studies demonstrated that the curcumin-conjugated contrast agent 2.1
interacts with β-amyloid aggregates resulting in a shortening of longitudinal relaxation time.
Thus, complex 2.1 has potential to be an efficient, β-amyloid-specific contrast agent for MRI.
Additionally, conjugated complex 2.1 exhibits fluorescence, and the both the wavelength and
intensity of the emission of complex 2.1 change upon interaction with β-amyloid aggregates in
vitro. Thus, this probe is multimodal allowing for validation of the presence of β-amyloid
aggregates using orthogonal imaging modalities.

A myelin-specific, multimodal imaging agent for magnetic resonance, optical, and mass
spectrometric imaging
Myelin-targeted GdIII-containing complexes were synthesized by mimicking the
structural features of a known myelin-specific stain, LFB MBS. The texaphyrin framework was
used in this project because it has structural similarities to phthalocyanine and a cavity size that
accommodates GdIII. Five different texaphyrins were synthesized by changing the functional
groups of the side chains of the texaphyrins. These new complexes contained methyl esters,
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carboxylates, and sulfonates. Ex vivo mouse brain samples were stained with these GdIII
texaphyrin complexes and imaged using optical microscopy, laser spray ionization vacuum mass
spectrometric imaging, and MRI. These ex vivo imaging studies demonstrated that the acid
functional groups containing neutral GdIII-containing texaphyrins have affinity toward myelin
rich regions in the brain tissue.
Future Directions
Improvements in synthesis of conjugate 2.1 and modification of the structure for potentially
interesting studies
In the synthesis of conjugate 2.1, improvements can be made to the synthesis of 2.1d by
using a milder base such as K2CO3 instead of NaOMe. Initially, NaOMe was chosen to peroform
conjugation at an enolic oxygen; however, phenol can be deprotonated using K2CO3, which is
milder than NaOMe, and should minimize the formation of multiple conjugation products
leading to an increased yield of desired product. Another improvement that can be made in the
synthesis is the addition of the isothiocyanate-containing GdIIIDTPA, 2.1f, dropwise to the basic
curcumin solution. This will avoid lengthened exposure of the isothiocyanate group to a basic
environment and could minimize the potential hydrolysis of isothiocyanate.
The effect of the structure of the conjugate 2.1 on interaction with β-amyloid aggregates
is one of the parameter that is important to study. One of the structural features that can be easily
changed in conjugate 2.1 is the amine linker length. Another structural feature that can be altered
is the conjugation site. The synthesis of conjugates with different linker lengths and different
sites of attachment will help in understanding the important factors needed to design more
effective β-amyloid-targeted contrast agents. The synthesis of neutral analogues of conjugate 2.1

100

is another potentially interesting study. Neutral complexes will enable the penetration of
analogues of complex 2.1 through blood brain barrier and facilitate the in vivo imaging. Because
the size of amyloid deposits are often microns in diameter, the use of high field MRI for βamyloid plaque imaging is desirable because high field strength MRI enables high resolution
imaging. Synthesis of analogues of 2.1 with metal complexes that have a better relaxivity in high
field strengths such as EuII cryptates is an interesting area of study to obtain contrast enhanced
images of β-amyloid deposits at high field strengths.
Investigation of the ability of conjugate 2.1 to modulate β-amyloid peptide aggregation
In vitro binding studies that were discussed in Chapter 3 demonstrated the ability of the
curcumin moiety in conjugate 2.1 to interact with the pre-formed β-amyloid aggregates. The
interaction of curcumin is not limited to labeling of β-amyloid plaques, but also is reported to
disrupt the existing β-amyloid deposit and inhibit the formation of β-amyloid oligomers and
fibrils. Because of these desirable properties, curcumin is widely studied as a potential
therapeutic for Alzheimer’s disease. However, the hydrophobic nature of the curcumin molecule
renders it insoluble in aqueous solvents limiting its use. Because curcumin conjugate 2.1 is
soluble in aqueous solutions, interacts with β-amyloid aggregates similar to free curcumin, and
has imaging capabilities with MRI and fluorescence, it would be interesting to study the ability
of conjugate 2.1 to modulate the aggregation of β-amyloid. This study would be interesting
because it would expand our understanding of the interaction between this multimodal imaging
agent and β-amyloid and also our understanding of the positive or negative impact on the
function of the curcumin moiety due to conjugation. Additionally, investigation of the molecular
properties that are important for in vivo studies of the molecule, including permeability assays,
and cell viability assays will give more insight into the use of the molecule.
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The ability of 2.1 to modulate the aggregation of β-amyloid peptides can be studied in the
presence and absence of metal ions, including CuII or ZnII, that are relevant in Alzheimer’s
disease. The formation of aggregates and the morphology of the formed aggregates can be
investigated at different time points using gel electrophoresis and transmission electron
microscope, respectively.
Improvements of myelin targeted complexes 2.2–2.6 by changing structural features
Studies presented in Chapter 4 revealed the necessary structural features of complexes
2.2–2.6 to interact with myelin including acid functional groups. However, another interesting
study would be the investigation of the length of the linker between texaphyrin and acid
functional group. Because it is assumed that the interaction is taking place between acid
functional groups and myelin basic protein, the feasibility of the interaction likely depends on the
distance between the acid functional group and the metal ion. By synthesizing texaphyrin
complexes containing different linker lengths and performing ex vivo imaging with these stains,
the effect of chain length on interaction with myelin could be delineated. Furthermore, based on
the relaxivity of complexes 2.2–2.6, it can be assumed that the negatively charged acid
functional groups may coordinate to the metal center. This coordination results in a decreased
water-coordination number and decreased relaxivity for the complex. By changing the length of
side chains and by monitoring the relaxivity values, the interaction between the metal center and
acid functional groups can be understood. Furthermore,
determine the water-coordination numbers of the complexes.

17

O–NMR studies can be used to
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Improvements of sample preparation for MR imaging.
Use of agarose gel as the embedding medium for mouse brain imaging with MRI
produces lot of background noise because of the water content in the gel. To reduce background
noise and to obtain better images, embedding media with minimal water content should be used.
By using perflouropolyether (Fomblin, CAS = 69991-67-9) media to embed tissue, background
noise in MR image can be reduced.
Potential applications of texaphyrins 2.3–2.6 in other fields
Texaphyrin complexes are colored compounds that absorb in the visible region. Unlike
previously reported texaphyrins, new complexes 2.3–2.6 contain carboxylate and sulfonate
groups in their side chains. These functional groups can potentially be used to anchor texaphyrin
complexes on solid surfaces. Hence, the synthesis of these texaphyrins with different metal ions
and the investigation of them as dye sensitizers for energy conversion would be an interesting
study.

103

APPENDIX A
1

H NMR spectrum

13

C NMR spectrum

104

1

H NMR spectrum

13

C NMR spectrum

105

1

H NMR spectrum

13

C NMR spectrum

106

1

H NMR spectrum

13

C NMR spectrum

107

1

H NMR spectrum

13

C NMR spectrum

108

1

H NMR spectrum

13

C NMR spectrum

109

1

H NMR spectrum

13

C NMR spectrum

110

1

H NMR spectrum

13

C NMR spectrum

111

1

H NMR spectrum

13

C NMR spectrum

112

1

H NMR spectrum

13

C NMR spectrum

113

1

H NMR spectrum

13

C NMR spectrum

114

1

H NMR spectrum

13

C NMR spectrum

115

1

H NMR spectrum

13

C NMR spectrum

116

1

H NMR spectrum

13

C NMR spectrum

117

1

H NMR spectrum

13

C NMR spectrum

118

1

H NMR spectrum

13

C NMR spectrum

119

1

H NMR spectrum

13

C NMR spectrum

120

1

H NMR spectrum

13

C NMR spectrum

121

1

H NMR spectrum

13

C NMR spectrum

122

1

H NMR spectrum

13

C NMR spectrum

123

1

H NMR spectrum

13

C NMR spectrum

124

1

H NMR spectrum

13

C NMR spectrum

125

APPENDIX B

a.

b.

Figure B.1. HPLC Chromatogram of conjugate 2.1. a. detected using a photodiode array (254
nm trace shown) and b. Detected using a fluorescence detector (λex = 395 nm and λem = 521 nm).

126

a.

b.

Figure B.2. HPLC Chromatogram of conjugate 2.5. Detected using a photodiode array: a. 210
nm and b. 476 nm traces shown.
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a.

b.

Figure B.3. HPLC Chromatogram of conjugate 2.6. Detected using a photodiode array: a. 210
nm and b. 476 nm shown.
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Figure B.4. UV-vis absorption spectra of texaphyrin ligands 2.2L, 2.4L–2.6L: 2.2L (…); 2.4L
(=); 2.5L (· ―); and 2.6L (―).

Figure B.5. UV-vis absorption spectra of texaphyrin complexes 2.2–2.6: 2.2 (…); 2.3 (---); 2.4
(=); 2.5 (· ―); and 2.6 (―).
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Figure B.6. Emission spectra of texaphyrin complexes 2.2–2.6: 2.2 (…), λex = 485 nm; 2.3 (---),
λex = 470 nm; 2.4 (=), λex = 468 nm; 2.5 (· ―), λex = 490 nm; and 2.6 (―), λex = 492 nm.

Figure B.7. Excitation spectra of texaphyrin complexes 2.2–2.6: 2.2 (…), λem = 772 nm; 2.3 (--), λem = 767 nm; 2.4 (=), λem = 757 nm; 2.5 (· ―), λem = 775 nm; and 2.6 (―), λem = 775 nm.
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Table B.1 Texaphyrin 2.2 relaxation time measurements (trial 1).
Concentration
(mM)
0.55
0.28
0.14
0.07
0.00

T1 (s)

1/T1 (s–1)

0.092
0.176
0.350
0.629
2.913

10.9
5.68
2.86
1.59
0.340

Table B.2 Texaphyrin 2.2 relaxation time measurements (trial 2).
Concentration
(mM)
0.55
0.28
0.14
0.07
0.00

T1 (s)

1/T1 (s–1)

0.090
0.180
0.346
0.626
2.925

11.1
5.71
2.87
1.60
0.350

Table B.3 Texaphyrin 2.2 relaxation time measurements (trial 3).
Concentration
(mM)
0.55
0.28
0.14
0.07
0.00

T1 (s)

1/T1 (s–1)

0.090
0.175
0.348
0.624
2.890

11.1
5.56
2.89
1.60
0.340
12

12

y = 19.68x + 0.23
R² = 0.999

1/T1 (s–1)

1/T1 (s–1)

y = 19.26x + 0.26
R² = 0.999

0
0.00

0.30
Concentration (mM)

Figure B.8. Relaxivity plot of 2.2 (trial 1).

0.60

0
0.00

0.30
Concentration (mM)

0.60

Figure B.9. Relaxivity plot of 2.2 (trial 2).
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12

1/T1 (s–1)

y = 19.63x + 0.22
R² = 0.999

0
0.00

0.30
Concentration (mM)

0.60

Figure B.10. Relaxivity plot of 2.2 (trial 3).

Table B.4 Texaphyrin 2.3 relaxation time measurements (trial 1).
Concentration
(mM)
0.57
0.29
0.14
0.07
0.04

T1 (s)

1/T1 (s–1)

0.135
0.253
0.512
0.840
2.969

7.41
3.95
1.95
1.19
0.340

Table B.5 Texaphyrin 2.3 relaxation time measurements (trial 2).
Concentration
(mM)
0.57
0.29
0.14
0.07
0.04

T1 (s)

1/T1 (s–1)

0.129
0.251
0.490
0.850
2.953

7.75
3.98
2.04
1.18
0.340
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Table B.6 Texaphyrin 2.3 relaxation time measurements (trial 3).
Concentration
(mM)
0.57
0.29
0.14
0.07
0.04

T1 (s)

1/T1 (s–1)

0.129
0.253
0.474
0.870
2.940

7.75
3.98
2.04
1.18
0.340

8

9
y = 13.56x + 0.06
R² = 0.998

1/T1 (s–1)

1/T1 (s–1)

y = 12.91x + 0.12
R² = 0.997

0
0.00

0
0.60 0.00
Concentration (mM)

Concentration (mM)

Figure B.11. Relaxivity plot of 2.3 (trial 1).

Figure B.12. Relaxivity plot of 2.3 (trial 2).

9

1/T1 (s–1)

y = 13.55x + 0.07
R² = 0.998

0
0.00

0.60
Concentration (mM)

Figure B.13. Relaxivity plot of 2.3 (trial 3).
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Table B.7 Texaphyrin 2.4 relaxation time measurements (trial 1).
Concentration
(mM)
0.22
0.11
0.05
0.03
0.00

T1 (s)

1/T1 (s–1)

0.344
0.730
1.210
1.680
2.810

2.91
1.37
0.83
0.60
0.360

Table B.8 Texaphyrin 2.4 relaxation time measurements (trial 2).
Concentration
(mM)
0.22
0.11
0.05
0.03
0.00

T1 (s)

1/T1 (s–1)

0.339
0.730
1.200
1.670
2.860

2.95
1.37
0.83
0.60
0.350

Table B.9 Texaphyrin 2.4 relaxation time measurements (trial 3).
Concentration
(mM)
0.22
0.11
0.05
0.03
0.00

T1 (s)

1/T1 (s–1)

0.350
0.740
1.190
1.620
2.840

2.86
1.35
0.84
0.62
0.350
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3.50
y = 11.65x + 0.26
R² = 0.989

y = 11.86x + 0.25
R² = 0.988
1/T1 (s–1)

1/T1 (s–1)

3.50

0.00
0.00

0.13

0.00
0.00
0.25

Figure B.14. Relaxivity plot of 2.4 (trial 1).

Figure B.15. Relaxivity plot of 2.4 (trial 2).

3.50

1/T1 (s–1)

y = 11.38x + 0.27
R² = 0.989

0.13
Concentration (mM)

Figure B.16. Relaxivity plot of 2.4 (trial 3).

0.25

Concentration (mM)

Concentration (mM)

0.00
0.00

0.13

0.25
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Table B.10 Texaphyrin 2.5 relaxation time measurements (trial 1).
Concentration
(mM)
0.80
0.40
0.20
0.10
0.00

T1 (s)

1/T1 (s–1)

0.1093
0.2184
0.4347
0.7392
3.8600

9.15
4.58
2.3
1.35
0.260

Table B.11 Texaphyrin 2.5 relaxation time measurements (trial 2).
Concentration
(mM)
0.80
0.40
0.20
0.10
0.00

T1 (s)

1/T1 (s–1)

0.1086
0.2200
0.4263
0.7370
3.8610

9.21
4.55
2.35
1.36
0.260

Table B.12 Texaphyrin 2.5 relaxation time measurements (trial 3).
Concentration
(mM)
0.80
0.40
0.20
0.10
0.00
10

T1 (s)

1/T1 (s–1)

0.1043
0.2153
0.4244
0.7370
3.8420

9.59
4.64
2.36
1.36
0.260
10
y = 11.19x + 0.19
R² = 0.999

1/T1 (s–1)

1/T1 (s–1)

y = 11.14x + 0.19
R² = 0.999

0
0.00

0.50
Concentration (mM)

Figure B.17. Relaxivity plot of 2.5 (trial 1).

1.00

0
0.00

0.50
Concentration (mM)

1.00

Figure B.18. Relaxivity plot of 2.5 (trial 2).
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12

1/T1 (s–1)

y = 11.68x + 0.14
R² = 0.999

0
0.00

0.50
1.00
Concentration (mM)
Figure B.18. Relaxivity plot of 2.5 (trial 2). Figure
B.19. Relaxivity plot of 2.5 (trial 3).
Table B.13 Texaphyrin 2.6 relaxation time measurements (trial 1).
Concentration
(mM)
1.02
0.51
0.26
0.13
0.00

T1 (s)

1/T1 (s–1)

0.0830
0.1463
0.2702
0.6137
3.8600

12.05
6.83
3.70
1.63
0.260

Table B.14 Texaphyrin 2.6 relaxation time measurements (trial 2).
Concentration
(mM)
1.02
0.51
0.26
0.13
0.00

T1 (s)

1/T1 (s–1)

0.0810
0.1456
0.2615
0.6212
3.8610

12.35
6.87
3.82
1.61
0.260

137

Table B.15 Texaphyrin 2.6 relaxation time measurements (trial 3).
Concentration
(mM)
1.02
0.51
0.26
0.13
0.00

T1 (s)
0.0829
0.1467
0.2636
0.6192
3.8420

1/T1 (s–1)
12.06
6.82
3.79
1.61
0.260

14

14

1/T1 (s–1)

1/T1 (s–1)

y = 11.63x + 0.44
R² = 0.995

0
0.00

0.60
Concentration (mM)

1.20

Figure B.20. Relaxivity plot of 2.6 (trial 1).

1/T1 (s–1)

y = 11.63x + 0.46
R² = 0.994

0.60
Concentration (mM)

Figure B.22. Relaxivity plot of 2.6 (trial 3).

0.60
Concentration (mM)

1.20

Figure B.21. Relaxivity plot of 2.6 (trial 2).
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Figure B. 23. Isotopic distribution of texaphyrin 2.4. The mass spectrum was obtained using
LSIV, sample was coated with 2-NPG matrix.

Figure B. 24. Ion mobility mass spectrometric studies of texaphyrin 2.4. The sample was coated
with 2-NPG matrix and mass spectrum was obtained using LSIV. a Two dimensional ion
mobility plot of drift time vs m/z. Bright spots highlighted by yellow circles depict the two
signals obtained for +1 complex of 2.4 at m/z 921. b Chemical structures of two possible
confirmations for texaphyrin 2.4. c Extracted mass spectra for the two signals.
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Figure B. 25. Light microscopic images of coronal sections of intact mouse brain stained with
texaphyrin 2.4. The mouse brain was sectioned after obtaining MRI to confirm stain distribution.
Panel (a) shows representative brain images from 0.62 to –3.40 mm Bregma. Panel (b) shows
high magnification images of myelinated regions and the magnified area is represented with a
black square containing respective number in panel (a). Slice thickness = 200 µm, Scale Bars
represent 1 mm.

Figure B. 26. R1-maps of mouse brains stained with texaphyrin 3 and unstained control marked
with five regions of interest that were used to calculate the enhancement of relaxation rate.
Myelin-rich and myelin-poor regions are marked by yellow and red lines, respectively.
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Table B. 16. Values of regions of interest used to calculate enhancement of R1.
Area

Mean

Min

Max

0.062

0.002

0.002

0.003

0.391

0.002

0.002

0.003

0.031

0.003

0.002

0.003

0.266

0.003

0.002

0.003

0.469

0.003

0.002

0.003

0.188

0.001

0.001

0.001

0.172

0.001

0.001

0.001

0.172

0.001

0.001

0.001

0.281

0.001

0.001

0.001

0.359

0.001

0.001

0.002

0.203

8.03E-04

7.24E-04

9.04E-04

0.266

9.58E-04

8.56E-04

0.001

0.25

9.79E-04

8.36E-04

0.001

0.578

8.67E-04

7.19E-04

0.001

0.016

9.43E-04

9.43E-04

9.43E-04

0.312

6.42E-04

5.98E-04

7.05E-04

0.312

5.28E-04

4.74E-04

5.90E-04

0.219

5.11E-04

4.76E-04

5.70E-04

0.359

5.49E-04

5.24E-04

5.96E-04

0.266

5.92E-04

5.26E-04

6.50E-04

Myelin-richStained
Myelin-richStained
Myelin-richStained
Myelin-richStained
Myelin-richStained
Myelin-poorStained
Myelin-poorStained
Myelin-poorStained
Myelin-poorStained
Myelin-poorStained
Myelin-richUnstained control
Myelin-richUnstained control
Myelin-richUnstained control
Myelin-richUnstained control
Myelin-richUnstained control
Myelin-poorUnstained control
Myelin-poorUnstained control
Myelin-poorUnstained control
Myelin-poorUnstained control
Myelin-poorUnstained control

Avg =
0.0026

% increase =
160

Fold increase
= 2.6

% increase =
61.2

Fold increase
= 1.61

Avg =
0.001

Avg =
9.1E-4

Avg =
5.6E-4
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This appendix contains permissions to reproduce some of the material in this thesis from
Bentham Science Publishers from Vithanarachchi, S. M.; Allen, M. J. Current Molecular Imaging

2012, 1, 12–25 and from The Royal Society of Chemistry from Vithanarachchi, S. M.; Allen, M.
J. Chem. Commun. 2013, 49, 4148–4150.
This appendix also contains permissions obtained when writing Vithanarachchi, S. M.;
Allen, M. J. Current Molecular Imaging 2012, 1, 12–25.
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ABSTRACT
SYNTHESIS AND CHARACTERIZATION OF NEW Gd3+-CONTAINING
COMPLEXES AS POTENTIAL TARGETED CONTRAST AGENTS FOR MAGNETIC
RESONANCE IMAGING.
by
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Degree: Doctor of Philosophy
The focus of the research described in this thesis is the study of chemistry relevant to
target-specific contrast agents for magnetic resonance imaging (MRI). MRI is a widely used
technique in diagnostic medicine and biomedical research to obtain anatomical and physiological
details of soft tissues. Contrast agents are used to enhance the contrast of MR images by causing
changes to the chemical environment of water molecules. Clinically approved GdIII-containing
contrast agents for MRI are non-specific, and consequently, have limited utility. Target-specific
contrast agents represent one way to circumvent this limitation. In the research described in this
thesis, myelin and β-amyloid aggregates were selected as targets because they are important in
diagnosing neurological diseases. The myelin-targeted complexes were designed to mimic the
structural features of a known myelin-specific histology stain, and ex vivo mouse-brain staining
method was developed to test these complexes. Ex vivo staining studies (optical, MRI, and mass
spectrometry imaging) demonstrated the ability of these complexes to interact with the
myelinated regions in mouse brain tissue. Additionally, a β-amyloid-targeted agent was
synthesized by conjugating a GdIII-containing complex to curcumin. The binding ability of this
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complex with in vitro β-amyloid peptide aggregates was studied using relaxation time and
fluorescence measurements. This dissertation presents the synthesis, characterization, and in
vitro and ex vivo imaging of these complexes. The studies using these paramagnetic metal
complexes have the potential to enable a reliable method to observe structural changes in the
brain.
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